Product EMA FDA EN Other WHO Year Generic DrugBank ID ATC ChEMBL Indications Targets Last Update Abemaciclib Y Y N N 2017 N DB12001 L01EF03 CHEMBL3301610 Advanced Breast Cancer; Metastatic Breast Cancer KRAS; ERBB2; EIF4EBP1; CDK4; CDK6; CCND3; ESR1; NRAS; BRAF; CCND2; ESR2; TP53; CCND1; PGR; SMARCA4; PIK3CA; ABCB1; CDKN2A; MKI67 2025-04-02 Abiraterone Y Y N Y 2011 Y DB05812 L02BX03 CHEMBL254328 Metastatic Castration Resistant Prostate Cancer TP53; SRD5A2; CHEK2; AR; SRD5A1; APC; ATM; TSPYL1; CPB2; PTEN; YBX1; DSE; SRD5A3; CYP17A1 2025-04-02 Acalabrutinib Y Y N N 2017 N DB11703 L01EL02 CHEMBL3707348 Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma CYP3A4; ENO2; DXO; BTK; EN1; EPHB3; EEGV1; EPHX2; MS4A2; EPS15; EFNB2; ERBB4; TP53; EFNA1; FGR; TEC; EPHA8 2025-04-02 Aclarubicin N N N Japan N DB11617 L01DB04 CHEMBL502620 TOP2A; CSF2; SMN1 2025-04-02 Adagrasib N Y N N 2022 N DB15568 L01XX77 CHEMBL4594350 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer KRAS; GPM6B 2024-07-24 Afamitresgene Autoleucel N Y N N 2024 DB18592 CHEMBL4802254 Unresectable or metastatic synovial sarcoma 2024-10-30 Afatinib Y Y N Y 2013 N DB08916 L01EB03 CHEMBL1173655 Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer EGFR; PTEN; ERBB2; NRG1; EML4; ERBB4; KRAS; ALK; BRAF; PIK3CA; UHRF1; EN1; ERBB3; ROS1; ARF1; DVL2; DXO; NUP62 2025-04-02 Aflibercept Y Y N N 2011 N DB08885 S01LA05; L01XX44 CHEMBL1742982 Metastatic Colorectal Cancer (MCRC) VEGFA; PGF; VEGFC; PIGF; VEGFB 2025-04-02 Aldesleukin N Y Y N 1992 N DB00041 L03AC01 CHEMBL1201438 High Risk Neuroblastoma; Metastatic Melanoma; Metastatic Renal Cell Carcinoma CD40LG; CD2; VIM; TNFAIP1; IL2RA; CD40; FCGR3B; MAPK14; CBL; IL2RB; IL2RG; PRF1; VIPR1; TG; SOCS1; TYK2; ILF3; STAT4; CD244; EPCAM; PIK3CA; PIK3CB; CD28; FCGR2B; PIK3CG; IL2; FYN; MMP2; FCGR3A; NOP2 2025-04-02 Alectinib Y Y N N 2015 N DB11363 L01ED03 CHEMBL1738797 Refractory, metastatic Non small cell lung cancer ALK; DRD4; IDH2; BRAF; TP53; CYP3A4; HBEGF; EML4; ROS1; RET 2025-04-02 Alemtuzumab Y Y N N 2001 N DB00087 L04AA34 CHEMBL1201587 B-Cell Chronic Lymphocytic Leukemia; T-Cell Prolymphocytic Leukemia CD52; TP53; CXCL12 2025-04-02 Alitretinoin Y Y N N 1999 N DB00523 D11AH04; L01XF02 CHEMBL705 AIDS-related Kaposi's Sarcoma RXRG; RARB; RXRA; BCHE; CETP; RARA; HCN2; ERBB2; CD34; BCHEL1; CCR2; BCHEL3; EHMT2; CGA; SFTPA1; GCK; P2RY2; SERPINE1; RXRB; VDR; RARG 2025-04-02 Alpelisib Y Y N N 2019 N DB12015 L01EM03 CHEMBL2396661 Advanced Metastatic Breast Cancer PIK3R3; PIK3C3; PIK3CB; ESR1; MTOR; ERBB2; PIK3R5; HRAS; BRAF; PIK3R4; F5; PIK3C2A; TSC2; PIK3CG; PTEN; PIK3CD; TSC1; F7; F7R; PIK3C2B; FGFR2; TP53; FGFR3; NRAS; ESR2; RB1; FGFR1; PI4KA; PIK3C2G; PIK3R1; SGK1; CDK4; PIK3R2; MAP2K1; PIK3CA; PIK3R6 2025-04-02 Altretamine N N Y N 1990 N DB00488 L01XX03 CHEMBL1455 Ovarian Cancer; Ovarian Cancer Stage III CYP1A2 2024-02-07 Aminolevulinic Acid Y Y N N 1999 N DB00855 L01XD04 CHEMBL601 Basal Cell Carcinoma (BCC); Squamous Cell Carcinoma (SCC) BCL2 2024-02-07 Amivantamab Y Y N N 2021 N DB16695 L01FX18 CHEMBL4297774 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer EGFR; MET 2025-04-02 Amrubicin N N N Japan N 2002 DB06263 L01DB10 CHEMBL1186894 TOP2A 2024-02-07 Amsacrine N N N N 1987 N DB00276 L01XX01 CHEMBL43 Leukemia, Acute; Refractory Leukemia ATXN2; ATAD5; DRD1; CYP2D6; CBX1; EHMT2; CYP2C19; TOP2A; CYP2C9; CYP1A2; CYP3A4; BTF3P11; MTOR; TOP2B; HSD17B10 2025-04-02 Anastrozole N Y Y Y 1995 Y DB01217 L02BG03 CHEMBL1399 Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer MAP4K4; ERBB2; CPD; CSMD1; ESR1; PGR; CLDN11; ZNF613; IGF2; DLG2; TUBB1; CYP19A1; CYP1B1 2025-04-02 Apalutamide Y Y N N 2018 N DB11901 L02BB05 CHEMBL3183409 Nonmetastatic Prostate Cancer AR; BEVI 2024-07-24 Arsenic Trioxide Y Y N Y 2018 Y DB01169 L01XX27 CHEMBL1200978 Refractory Acute Promyelocytic Leukemia CDKN1A; PML; MYCN; TXNRD2; GSTO1; BIRC5; TERT; RARA; CCND1; MAPK3; MAPK10; IKBKB; MAPK1; JUN; EPO; IL6; FAS; SERPINE1; SMO; BDNF; DNMT1; TXNRD1; HSPA4; MT1A; FLT3; FGFR1 2025-04-02 Asciminib Y Y N N 2021 N DB12597 L01EA06 CHEMBL4208229 Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase BCR; ABL1 2025-04-02 Asparaginase Y Y N Y 1994 N DB00023 L01XX02 CHEMBL2108989 Acute Lymphoblastic Leukaemias (ALL) ASNS; SOD2; LPL; TYMS; MIR3117; HLA-DRB1; GATA3; GRIA1; TYMSOS; MYBBP1A; PYGL; PNPLA3; ETV6; ATF5; CPA2; MIR4268; MTHFR; NFATC2 2025-04-02 Atezolizumab Y Y N N 2016 N DB11595 L01FF05 CHEMBL3707227 Metastatic Non-Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Triple Negative Breast Cancer (TNBC); Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma MLH1; CTLA4; BRAF; FGFR3; ALK; MDM4; EGFR; MSH6; PBRM1; KRAS; JAK3; ARID1A; PTEN; CX3CL1; PIK3CA; CD274; HLA-DRA; STK11 2025-04-02 Avapritinib Y Y N N 2020 N DB15233 L01EX18 CHEMBL4204794 Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor CBL; PDGFRA; FLT3; KIT; DPT 2025-04-02 Avelumab Y Y N N 2017 N DB11945 L01FF04 CHEMBL3833373 Locally advanced disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic Merkel Cell Carcinoma (MCC); Metastatic disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC) ATM; MSH6; CD274; MLH1 2025-04-02 Axicabtagene Ciloleucel Y Y N N 2017 N DB13915 L01XX70 CHEMBL3989989 Refractory Diffuse large B-cell lymphoma NOS; Refractory High grade B-cell lymphoma Burkitt-like lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Relapsed Diffuse large B-cell lymphoma NOS; Relapsed High grade B-cell lymphoma Burkitt-like lymphoma; Relapsed Primary Mediastinal Large B-Cell Lymphoma CD19 2025-04-02 Axitinib Y Y N N 2012 N DB06626 L01EK01 CHEMBL1289926 Advanced Thyroid cancer DRD2; ABCG2; FLT4; FLT1; UGT1A9; PDGFRB; YES1; ABL1; FABP5; HIF1A; UGT1A8; UGT1A7; UGT1A10; PDGFB; PDGFRA; KDR; KIT; TP53; OR2B11; BRAF; VHL 2025-04-02 Azacitidine Y Y N N 2004 Y DB00928 L01BC07 CHEMBL1489 Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia ABL1; DNMT1; CBL; TP53; IL11; ATAD5; FLT3; GGT1; DNMT3A; TG; CD247; PLAU; GATA2; MTHFR; AR; PTPN11; ALDH1A1; NRAS; NR3C1; GMNN; TYMS; TET2; THPO; LIF; TAGLN; XRCC1; HTT; KRAS; AFP; GSTP1; SMAD3; CDA; NFE2L2; MYC; TRIT1; IDH1; HBB; MGMT; RORC; IDH2 2025-04-02 BCG Vaccine Y Y N Y N DB12768 L03AX03 CHEMBL2108905 Non-Invasive Bladder Urothelial Carcinoma; Recurrent Superficial Bladder Cancer; Urothelial Carcinoma Recurrent; Carcinoma in situ of urinary bladder PIK3CB; IL2; KLK3 2025-04-02 Belantamab Mafodotin Y Y N N 2020 N DB15719 L01FX15 CHEMBL4298209 Relapsed Or Refractory Multiple Myeloma TUBB1; TUBB2A; TUBA4A; TUBA1B; ECE1; TUBA1A; TUBA3C; TUBB; TUBB4B; TUBA3E; TUBB2B; TUBB4A; TUBA1C; TUBB8; TUBB6; TUBB3; TNFRSF17 2025-04-02 Belinostat N Y N N 2014 N DB05015 L01XH04 CHEMBL408513 Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified HDAC7; HDAC3; UGT1A1; GAPDHP1; HDAC10; MSTN; HDAC6; GAS1; KMT2A; FBXW7; GDF2; HDAC11; GARS1; GAS2; HDAC8; HDAC2; HDAC5; GDF9; GART; HDAC4; HDAC1; HDAC9 2025-04-02 Belotecan N N N South Korea N 2003 DB12459 L01CE04 CHEMBL2111084 TOP1 2024-02-07 Belzutifan Y Y N N 2023 N DB15463 L01XX74 CHEMBL4585668 Advanced Renal Cell Carcinoma CYP2C19; EPAS1; VHL; UGT2B17; PBRM1 2025-04-02 Bendamustine N Y Y Y 2008 Y DB06769 L01AA09 CHEMBL487253 Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma TP53; CD69; ATM 2025-04-02 Bevacizumab Y Y N Y 2004 N DB00112 S01LA08; L01FG01 CHEMBL1201583 Cervical Cancer Metastatic; Metastatic Colorectal Cancer (MCRC); Metastatic Non-Squamous Non-Small Cell Lung Cancer; Metastatic Renal Cell Carcinoma; Persistent Cervical Cancer; Recurrent Cervical Cancer; Recurrent Glioblastoma; Stage III epithelial ovarian cancer following initial surgical resection; Stage IV epithelial ovarian cancer following initial surgical resection; Fallopian tube cancer following initial surgical resection; Locally advanced nonsquamous non-small cell lung cancer; Primary peritoneal cancer following initial surgical resection; Recurrent Non-Squamous Non-Small Cell Lung Cancer; Recurrent Platinum-Sensitive Epithelial Ovarian Cancer; Recurrent Platinum-resistant Epithelial Ovarian Cancer; Recurrent platinum drug resistant Fallopian tube cancer; Recurrent platinum drug resistant primary peritoneal cancer; Recurrent platinum sensitive primary peritoneal cancer; Recurrent platinum-sensitive fallopian tube cancer; Unresectable Non-Squamous Non-Small-Cell Lung Cancer KRAS; EMSY; KIT; ANXA11; BRAF; ALK; VEGFB; CXCR2; EGFR; CCT3; GC; VHL; GGH; PRKCA; NF2; HRAS; CXCL8; PTEN; VEGFC; THBS2; HOXC10; RALBP1; MMP9; SHMT1; CXCR4; MMP2; TP53; PIK3CA; NF1; PDGFRB; SLC19A1; MGAT4A; F2R; EDN1; VEGFA; HSP90AB1; EML4; FOXF1; CSPG4; IDH1 2025-04-02 Bexarotene Y Y N N 1999 Y DB00307 L01XF03 CHEMBL1023 Refractory peripheral cutaneous T-cell lymphoma USP1; RXRG; MAPK8; BLM; NR1H3; RXRB; RXRA; NR1I2; KAT2A; HCN2; OPN1SW; CCND1 2025-04-02 Bicalutamide N Y Y Y 1995 Y DB01128 L02BB03 CHEMBL409 Stage D2 Prostatic carcinoma AR; BAX; CFLAR; KMT2D; BEVI; FST; CDH1; VDR; CYP2B6; KLK3 2025-04-02 Binimetinib Y Y N N 2018 N DB11967 L01EE03 CHEMBL3187723 Metastatic Melanoma; Unresectable Melanoma BRAF; KIT; APC; MAP2K3; NRAS; PIK3CA; MAP2K2; MAP2K4; NF1; MAP2K1; KRAS; JAK2; UGT1A1; MAP2K6; HRAS; PTEN; ATM; NR2F6; MAP2K5; MAP2K7 2025-04-02 Bleomycin N Y Y Y 1973 Y DB00290 L01DC01 CHEMBL403664 Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma CTLA4; SMAD2; PLAU; IFNG; BLMH; GJA1; WRN; F2R; BRCA1; NFE2L2; AFP; MAPK8; GSTM1; ADK; LIG1; CCL17 2025-04-02 Blinatumomab Y Y N N 2014 N DB09052 L01FX07 CHEMBL1742992 Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory; Relapsed B cell precursor Acute lymphoblastic leukemia ABL1; KMT2A; CD3D; CD247; BCR; CD3E; CD3G; GMFB; GLRA2; CD19 2025-04-02 Bortezomib Y Y N Y 2003 Y DB00188 L01XG01 CHEMBL325041 Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM) PSMB1; PSMA7; PSMB3; PSMA8; TP53; PSMD9; PSMA3; PSMC4; BDNF; PSMD10P2; PSME3; PRSS3; PSMB8; PSMC2; PIK3CA; PSMD8; PSMA1; PSMB10; PSMB11; PSMD4P1; BCL2L2; PSMC1; FLT3; BCL2; PSME4; PSMD12; NFKB1; PRSS2; PSMB2; PRSS1; PSMD5; PLAT; PIK3CG; PSMC1P1; PSMB9; CCND1; PSMD2; PSMA2; PSMD11; PSMD6; E2F1; PSMA6; F2; PIPSL; NFE2L2; HSPB2; PSMD10P1; FRA6F; PSMC5; PSMA5; AR; PSME1; F12; PSMD10; PSME2P2; HSPA4; PRB2; GATA2; CTSB; PSME2; PMAIP1; CTSL; DDIT3; PLG; PSMD13; PSMD1; CAPN1; PSMD3; PSMC6; SEM1; PSMC3IP; PSMB6; PSMA4; ADRM1; PSMB5; PSMD10P3; PSMB4; PSMD14; PSMF1; PSMC3; FGFR3; XIAP; PSMD4; PSMB7; PSMD7 2025-04-02 Bosutinib Y Y N N 2010 N DB06616 L01EA04 CHEMBL288441 Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia ABL1; CYP2C19; BCR; FCGRT; EPS15; STK10; FGF1; CAMK2G; FAU; FBLN2; MEGF6; LYN; FGR; STK4; MS4A2; BRAF; FAUNA@; ENO2; BRCA2; HCK; SRC; ERVT1; ENO1P1 2025-04-02 Brentuximab vedotin Y Y N N 2011 N DB08870 L01FX05 CHEMBL1742994 B-large cell anaplastic Lymphoma (Kiel Classification) refractory; Refractory Hodgkin Lymphoma; Post-autologous hematopoietic stem cell transplantation Hodgkin lymphoma TNFRSF8; TUBA1C; TUBB8; ALK; TUBB2A; TUBB1; TUBA1A; TUBB2B; TUBB; TUBB4A; TUBB3; TUBA3C; TUBB6; TUBA1B; TUBB4B; TUBA3E; E4F1; TUBA4A 2025-04-02 Brexucabtagene Autoleucel Y Y N N 2020 N DB15699 L01XL06 CHEMBL4594618 Refractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma CD19 2024-02-07 Brigatinib Y Y N N 2017 N DB12267 L01ED04 CHEMBL3545311 Metastatic Non-Small Cell Lung Cancer EGFR; TP53; ROS1; FLT3; DPH1; EML4; DPEP1; FGFR1; HBEGF; ALK; DXO 2025-04-02 Buserelin N N Y N 2017 N DB06719 L02AE01 CHEMBL2110824 Stage D2 Prostatic carcinoma GNRHR; IGFBP1 2024-02-07 Busulfan Y Y N N 1954 Y DB01008 L01AB01 CHEMBL820 Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia MTHFR; CYP2B6; CYP2C19; BCR; ABL1; ABCC3; CYP2D6; ADK; CYP2C9; GSTA1; CYP3A4; CYP1A2; GSTP1; SHBG; GALC; GSTM1; ITGAL; G6PD; THPO 2025-04-02 Cabazitaxel Y Y N N 2010 N DB06772 L01CD04 CHEMBL1201748 Refractory, metastatic hormone-refractory Prostate cancer TUBB1; TUBB2B; TUBA1B; ABCB1; TUBB4B; TUBB8; TUBB3; GCF1; TUBA1A; TUBA1C; TUBB; TUB; TUBB4A; TUBA3C; TUBB6; CYP3A5; IGF2; TUBA4A; CYP2C8; CYP3A4; TUBA3E; TUBB2A 2025-04-02 Cabozantinib Y Y N N 2012 N DB08875 L01EX07 CHEMBL2105717 Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer MET; FLT3; ROS1; KIT; TP53; GNA11; PTK2B; DRD4; NRAS; PIK3CA; ABL1; CFLAR; TEK; DRD2; KDR; HGF; PBRM1; YES1; CTNNB1; RET; VHL; HRAS 2025-04-02 Calaspargase Pegol N Y N N 2018 N DB14730 L01XX86 CHEMBL2108728 Acute Lymphoblastic Leukaemias (ALL) ASRGL1 2024-02-07 Capecitabine Y Y N Y 1998 Y DB01101 L01BC06 CHEMBL1773 Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma ZMIZ1; TYMSOS; REV3L; SLC19A1; PTGS2; EXO1; UPB1; NSUN3; CES1P1; CYP1A1; AREG; TMEM131L; SPRY2; LMNTD1; SMAD7; PHC1; SIRPA; NCOA7; CCDC70; CDX2; MGAT4A; SELE; CD96; PTEN; MAN1A1; GCGR; SLC22A7; PIK3CA; PPARD; FAT1; DLG5; MIR2054; KRAS; ANK3; TENM4; ABCG2; MLH1; VPS13D; UGT1A1; CCDC77; DPYD; CYP19A1; ADGRG7; SSU72; BRAF; ERBB2; TYMS; TP53; CES1; ATM; MSH6 2025-04-02 Capivasertib Y Y N N 2023 N DB12218 L01EX27 CHEMBL2325741 Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer TP53; ERBB2; AKT3; PTEN; AKT2; ESR1; ESR2; MTOR; AKT1; PIK3CA 2025-04-02 Capmatinib Y Y N N 2020 N DB11791 L01EX17 CHEMBL3188267 Metastatic Non-Small Cell Lung Cancer MET; DRD4; PTEN 2025-04-02 Carboplatin N Y Y Y 1989 Y DB00958 L01XA02 CHEMBL1351 Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma PIK3CA; XRCC1; PSORS1C1; TNF; CDSN; MAP3K1; MLH1; NR1I2; CDK2; GSTP1; BRCA1; MAPT; NRG3; ALDH1A1; ADAMTSL4-AS1; MUCL3; BCL2; GSR; HCP5; ACSS2; USP1; SERPINC1; DOCK8; APEX1; RRM1; NF2; POLK; ETS2; EGFR; TP73; PRRC2A; VEGFA; LIG3; MTHFR; NRG1; KAT2A; ABCB1; RNF8; SLCO1B3; ATP7B; NRAS; SLC19A1; UGT1A1; FGFR1; TRIM5; OR4D6; CDKN1A; ASS1; RAF1; PPP1R18; ERCC2; BRCA2; ERBB3; EMSY; DDX53; HSD17B10; SERPINA5; FNTB; C6orf15; VDR; XYLT2; PTEN; ROS1; GPX5; MSH6; CDKN2A; ERBB2; SLC31A1; KRAS; HRAS; ALDH3A1; DSCAM; SCN10A; MSH5; ATP7A; ATAT1; BIRC5; TIGD1; MAD1L1; CYP3A5; GCLC; HLA-C; GSTT1; TP53; EIF4E2; ERCC1 2025-04-02 Carfilzomib Y Y N N 2009 N DB08889 L01XG02 CHEMBL451887 Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM) PSMA7; PSMD3; PSMD6; PSMD11; PSMB5; PSMC1P1; PSMB6; PSMD2; PSMD10; NFE2L2; PSMC2; PSMA4; PSMA3; PSME4; PSMC1; PSMB1; PSMB9; PSMD13; PSMC3; PSME3; PSMC6; PSMB11; PSMC3IP; PSMD5; PSMC4; PSMA1; PSMD10P2; KDR; PSMD8; ADRM1; PSMB8; PSMA8; PSMB2; PSMA6; PIPSL; PSMD10P1; SEM1; PSMB7; PSMD1; PRB2; PSMB3; PSMD7; PSME2; PSME1; PSMD9; VEGFA; AR; PSMB10; PSMC5; PSMA2; PSMD12; PSMD4; PSMD4P1; PSME2P2; PSMB4; PSMD10P3; FRA6F; PSMA5; PSMD14; PSMF1 2025-04-02 Carmofur N N N Japan N DB09010 L01BC04 CHEMBL460499 CYP3A4 2024-02-07 Carmustine Y Y N N 1977 Y DB00262 L01AD01 CHEMBL513 Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma CYP2C19; GSR; ALDH1A1; E2F1; MGMT; CYP1A2; CYP3A4; CYP2C9; CYP2D6; PLAU; G6PD 2025-04-02 Cemiplimab Y Y N N 2018 N DB14707 L01FF06 CHEMBL4297723 Metastatic cutaneous squamous cell carcinoma; Locally advanced cutaneous squamous cell carcinoma, and not a candidate for curative surgery or curative radiation ALK; PDCD1; GM2A; EGFR; CDK12; CD274; ROS1 2025-04-02 Ceritinib Y Y N N 2014 N DB09063 L01ED02 CHEMBL2403108 Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer ROS1; CYP3A4; DPYS; TSSK1B; MAP2K1; NPM1; EML4; DPH1; NRAS; IGF1R; HBEGF; DPEP1; ABCB1; TP53; ALK; FGF12; INSR 2025-04-02 Cetuximab Y Y N N 2004 N DB00002 L01FE01 CHEMBL1201577 Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN); Metastatic Colorectal Cancer (MCRC); Metastatic Squamous Cell Carcinoma of the Head and Neck; Recurrent Squamous Cell Carcinoma of the Head or Neck; Regionally Advanced Squamous Cell Carcinoma of the Head and Neck TGFA; IDH1; ERBB2; EGFR; BAX; NF2; ERBB3; MET; EREG; BRAF; PIK3CA; MAP2K1; NRAS; HBEGF; FCGR3A; CDKN2A; MGAT4A; TOP1; SMAD4; NRG2; GC; AREG; HRAS; BDNF; NT5E; CTNNB1; VPS37A; TP53; NRG3; DXO; EGF; PTP4A3; PTEN; BTC; KRAS; CXCL8; NRG1 2025-04-02 Chlorambucil N Y Y Y 1957 N DB00291 L01AA02 CHEMBL515 Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma NFKB1; FANCC; MGMT; CXCL12; GFER; TP53; GSTM1; BAZ2B; RORC; ERBB2 2025-04-02 Ciltacabtagene Autoleucel Y Y N N 2022 N DB16738 CHEMBL4802263 Refractory Multiple Myeloma, Relapsed Multiple Myeloma TNFRSF17 2025-04-02 Cisplatin N Y Y Y 1978 Y DB00515 L01XA01 CHEMBL2068237 Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma NRAS; PRL; STAT1; PIK3CA; RRM1; MTHFD1; GPX5; NRG1; MSH2; IL6; KDM4E; MAP3K1; PTEN; RGS4; GABPA; XRCC3; ATRX; HPGD; TP53; DCBLD1; CXCR4; GRP; MYCN; GCLM; ERCC4; FANCA; MYC; ABCC4; GSTP1; PLAU; GSTT1; ERCC1; MGMT; ABCC5; MLLT3; BRCA1; CBX1; KRT20; ALDH1A1; CDC25C; GADD45A; UBE2I; BRCA2; SLC19A1; ACTL6A; MUTYH; ERCC2; RECQL; TP73; LIF; ATR; MDM2; ADH1C; OVOL2; NTRK2; MT1F; CCND1; BCL2; HSPA8; APEX1; CYBA; ALOX15; POLR1G; FANCC; IDH1; AQP9; FXN; CGA; EHMT2; ALK; FASLG; ARID1B; H2AC25; HMGB1; TERC; IFNG; XIAP; MPHOSPH8; ESR1; SMARCA4; RB1; E2F1; PPP1R13L; BIRC7; DRAM1; XRCC5; DFFB; G6PD; MT1H; EGFR; ANPEP; GCLC; BAX; ATP7B; BIRC5; CASP3; HRAS; MDH2; PPARD; HSD17B10; RAD51C; SEMA6A; ERCC6; CHEK1; DNMT1; FGFR3; CLCN6; DDIT3; ATM; GNAS; FGFR1; GALNT18; CSNK2A3; WFS1; CDH17; TYMS; TMEM43; ABCC1; MECP2; KAT2A; RARS1; TGM2; ASS1; NFE2L2; OSGEP; SLC22A1; AURKA; KRAS; HEXB; XRCC1; MIR21; HSPA4; TPMT; MAPT; BLMH; ACSS2; NF2; GSTM4; NHLH1; CD44; SYNE3; RAF1; HTR4; GALNT14; FAS; NR1I2; TOP1 2025-04-02 Cladribine Y Y N N 1993 Y DB00242 L04AA40; L01BB04 CHEMBL1619 Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL) DCK; XIAP; CDKN1A; RRM2; RRM1; RRM2B; YES1; DIABLO; NFE2L2; BCL2L2; TP53; NT5C1A; ADA; TGFB1; IL2RA 2025-04-02 Clofarabine Y Y N N 2004 Y DB00631 L01BB06 CHEMBL1750 Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis NIPSNAP2; POLA2; POLA1; POLD1; APBB1; POLD2; GBA1LP; RRM1; POLE2; POLE3; RRM2; POLD4; RRM2B; PRIM2; AR; PRIM1; POLE; POLD3; FLT3 2025-04-02 Cobimetinib Y Y N N 2015 N DB05239 L01EE02 CHEMBL2146883 Metastatic Melanoma; Unresectable Melanoma MAP2K2; RAF1; CBL; BRAF; ARAF; NF1; NR2F6; MAP2K6; ERCC2; PTEN; MAP2K4; MAP2K5; PIK3CA; CDKN2A; MAP2K3; MAP2K7; KRAS; NRAS; MAP2K1 2025-04-02 Copanlisib N Y N N 2017 N DB12483 L01EM02 CHEMBL3218576 Relapsed Follicular Lymphoma PIK3R2; PIK3CA; PIK3R1; PIK3R3; PIK3C2A; NRAS; PIK3C2G; PIK3C2B; PIK3CD; PIK3R4; PIK3R6; F7R; PIK3CG; PIK3CB; PIK3C3; KIT; F7; AURKB; F5; ETFB; PIK3R5; PTEN 2025-04-02 Cosibelimab N Y N N 2024 N DB15770 CHEMBL4297729 Locally advanced or metastatic cutaneous squamous cell carcinoma CD274 2025-04-02 Crizotinib Y Y N N 2011 N DB08865 L01ED01 CHEMBL601719 Metastatic Non-Small Cell Lung Cancer MET; ROS1; PTPN12; KRAS; NTRK1; AREG; ABCB1; HBEGF; NPM1; NTRK2; BRAF; TP53; IGF1R; PIK3CA; ARID2; KIT; HRAS; JAK2; EML4; ERBB2; DRD4; ABL1; EGFR; ALK; NTRK3 2025-04-02 Cyclophosphamide N Y Y Y 1959 Y DB00531 L01AA01 CHEMBL88 Acute Lymphoblastic Leukaemias (ALL); Acute Myelocytic Leukemia; Adenocarcinoma of the Ovaries; Breast Cancer; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia (CLL); Chronic Myeloid Leukemia (CML); Disseminated Neuroblastoma; Ewing's Sarcoma; Lung Cancers; Lymphoma, Hodgkins; Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Waldenstrom's Macroglobulinemia (WM); Advanced Alibert-Bazin syndrome; Histiocytic lymphoma; Metastatic gestational trophoblastic tumor; Mixed-cell type lymphoma; Refractory Small cell lung cancer; Relapsed Wilm's tumor EHMT2 2024-07-25 Cytarabine Y Y N Y 1969 Y DB00987 L01BC01 CHEMBL803 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia CYP2C19; VDR; SLCO1B1; MIR4268; POLD4; POLD3; NTRK1; CDA; CYP2E1; TYMS; GSTP1; CPT1A; CYP3A4; MIR3117; IL1B; PNPLA3; KIT; ABCC3; NOS3; CYP2D6; IKZF1; CBR3; PRIM1; SLC29A1; NRG1; UGT1A1; NQO1; DOK5; CYP1A2; TP53; PRIM2; HSPA4; WT1; RRM1; quinone dehydrogenase 2; CCND1; ABCC4; NRAS; GATA3; RRM2; POLD1; ALK; NT5C2; EHMT2; MED12L; RRM2B; POLA1; IDH1; XIAP; TYMSOS; BRD10; KMT2A; CYP2C9; CSF2; POLB; TP73; POLA2; P2RY12; POLE3; ITGAV; NT5C3A; NCOA3; FCGR3B; POLE2; FCGR3A; TPMT; IDH2; POLD2; SLC22A12; ATF5; BIRC5; POLE; IGHMBP2; FLT3; SULT2B1; BMP7; RUNX1; ADH1A; MAGEA1; LINC00251 2025-04-02 Dabrafenib Y Y N N 2013 N DB08912 L01EC02 CHEMBL2028663 Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation NRAS; IDH1; BRAF; EML4; MAP2K1; EFNA2; G6PD; HRAS; MAP2K3; MAP2K4; MAP2K7; TP53; KRAS; HLA-DRB1; ATXN1L; PTEN; PIK3CA; AKT1; RAC1; ALK; MITF; MAP2K2; NF1; SMARCA4; MAP2K5; CDKN2A; MAP2K6 2025-04-02 Dacarbazine N Y Y Y 1975 Y DB00851 L01AX04 CHEMBL476 Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor CYP1A2; POLA2; EPM2AIP1; CYP2C9; CYP3A4; CYP1A1; BAX; CYP2D6; CXCL8; MGMT; FN1; GSTM1; ADK; PLAU; CYP2C19 2025-04-02 Dacomitinib Y Y N N 2018 N DB11963 L01EB07 CHEMBL2110732 Metastatic Non-Small Cell Lung Cancer EGFR; ERBB4; ERBB2; EN1; DXO; ERBB3 2025-04-02 Dactinomycin N Y N Y 1964 Y DB00970 L01DA01 CHEMBL1554 Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer CEL; EHMT2; RORC; ALOX15; BGLAP; TOP2A; APEX1; NRG1; AR; MTR; COIL; CSF1; RECQL; PIK3CB; TNFRSF8; RXRA; TFPI; CYP3A4; PPARD; DDIT3; BDNF; AFP; VDR; CD5; NTF3; THRB; HTT; CYP2D6; MTHFR; ESR1; TNFRSF1B; BIRC5; NR3C1; CYP1A2; GRB2 2025-04-02 Daratumumab Y Y N N 2015 N DB09331 L01FC01 CHEMBL1743007 Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma GMPR; CD38 2025-04-02 Daratumumab, Hyaluronidase N Y N N 2020 N DB09331 L01FC01 CHEMBL1743007 Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma GMPR; CD38 2025-04-02 Darolutamide Y Y N N 2019 N DB12941 L02BB06 CHEMBL4297185 Non-mestatatic castrate-resistant prostate cancer BEVI; AR 2025-04-02 Dasatinib Y Y N Y 2006 Y DB01254 L01EA02 CHEMBL1421 Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML) PDGFRA; SYK; FYN; AXL; BRAF; AR; SIK2; SMAD3; LCK; PLK4; MAP3K10; SLK; YES1; ERBB4; SRC; BCR; IRAK4; BRCA2; STAT5B; BTK; CRKL; LYN; FGFR1; MAPK14; PPARD; BLK; DDR2; ABL2; ABI1; SRMS; TET2; TEC; MS4A2; JAK2; MAP2K1; MAP3K20; FBLN2; LIMK1; ABCB1; PTK6; NF1; ERBB2; TAOK1; CDC42BPA; DYRK3; FRK; PIK3CA; MAP2K2; IDH2; CSF3R; PKN2; HRAS; KDR; IDH1; TNK2; GMNN; FES; FGR; KIT; CBL; HCK; ABCG2; ACVR1; ARID1A; FAU; FAUNA@; EPHA2; FGFR3; APC; KRAS; MAP4K5; MINK1; ABL1; CSF1R; PDGFRB; AURKB 2025-04-02 Datopotamab Deruxtecan Y Y N N 2025 N DB16410 L01FX35 CHEMBL4297939 Unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer UTS2R 2025-04-02 Daunorubicin N Y Y Y 1979 Y DB00694 L01DB02 CHEMBL178 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia AKR1C4; HDAC1; DOK5; HDAC9; ATP7B; TPMT; TYMSOS; KMT2A; FAS; GSTP1; ABCC1; GSTM3; IKZF1; DNMT3A; UGT1A1; GSTA2; TOP2A; USP1; HDAC10; TYMS; RECQL; AKR1C3; CYP2J2; ATF5; POLK; NOS3; LINC00251; CBFB; BLM; APEX1; SLC15A1; IDH2; NPM1; SLC22A17; HDAC3; COL1A2; TOP1; HDAC4; WT1; CDK2; APP; FLT3; HDAC8; SLCO6A1; TOP2B; EHMT2; RUNX1; CDA; ABCA1; SZRD1; ABCC10; SLCO1B1; ABCB1; MAPT; SLC22A7; GPX3; HDAC7; BMP7; MIR3117; HDAC2; ABCG2; CBR1; SERPINA6; KDM4E; THRB; SETD4; CYP1A1; NRP2; HDAC5; HDAC11; XDH; GATA3; HTT; MAN1B1; SOD2; IGHMBP2; SLCO4C1; ANXA5; AKR7A2; MIR4268; HDAC6; SLC13A3; ABCB11; DCK; MTHFR; RPSA; ABCC9; PNPLA3; CPT1A; AR; IDH1 2025-04-02 Daunorubicin, Cytarabine Liposome Y Y N N 2017 Y DB00694 L01XY01; L01DB02 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia 2021-10-28 Decitabine Y Y N N 2006 Y DB01262 L01BC08 CHEMBL1201129 Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS) KRAS; CDKN2D; CCND2; TP53; APC; MAGEA1; THBS1; FLT3; DNMT3A; CTAG1B; CR2; CYP27B1; RB1; KMT2A; NR5A1; IDH2; GSTP1; GMNN; IL2RA; TGM2; DNMT1; LIF; MUC2; IDH1 2025-04-02 Decitabine , Cedazuridine Y Y N N 2020 N Not found in DrugBank L01BC58 Acute Myeloid Leukaemia 2023-08-01 Degarelix Y Y N N 2008 N DB06699 L02BX02 CHEMBL415606 Advanced Prostate Cancer GNRHR; GNRHR2 2024-07-24 Denileukin Diftitox N Y N N 1999 N DB00004 L01XX29 CHEMBL1201550 Cutaneous T-Cell Lymphoma (CTCL) IL2RA; IL12RB1; IL12RB2; EEF2; IL2RB; IL2RG 2025-04-02 Denosumab Y Y N N 2010 N DB06643 M05BX04 CHEMBL1237023 Giant cell tumor of the bone; Refractory Hypercalcemia of malignancy TNFSF11; BRAF; TNFRSF11A 2025-04-02 Dexamethasone Y Y N Y 1958 Y DB01234 S03BA01; S02BA06; S01CB01; S01BA01; R01AD03; H02AB02; D10AA03; D07XB05; D07AB19; C05AA09; A01AC02 CHEMBL384467 Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF) APOB; F2RL1; CARTPT; FABP1; PTGDR; TYMS; CYP2D6; VCAM1; NR5A1; HSPA8; BMP7; TG; IGFBP1; CHKA; SDS; TJP1; GLS; GATA3; RET; CYP2C9; NFE2L2; CDH17; GSTP1; BIRC5; ANXA1; JUNB; CYP3A4; PYGL; ACTC1; CDK2; NR3C1; FOLR1; TSC22D3; SMAD3; CD86; UBR1; JAK3; SLC2A4; RPS19; DPEP1; CHRM3; SI; CCL17; BDM; CHAT; HYAL2; SOAT1; NR3C2; KDR; KRT19; PTH1R; MT1F; SAG; TGFBR3; LINC00251; CYP1A2; NRG1; NTRK1; NR1I2; CTNNB1; HTR7; THRSP; F9; S100A10; BCL2L11; IRS2; RARA; NPPC; CDK4; ALK; RELA; VEGFA; SFTPA1; UGT1A1; AR; CYP2C19; CRISPLD2; SERPINE1; LIF; TDO2; PZP; GGT1; AGTR1; TEAD1; DOK5 2025-04-02 Diethylstilbestrol N N Y N 1973 N DB00255 G03CC05; G03CB02; L02AA01 CHEMBL411 MYC; GMNN; ESRRB; ESR1; RORC; AMH; BDKRB1; HRAS; LPO; ERBB2; CP; NR1I2; BCL2; CYP1A2; BCYRN1P2; PTGES3; BDKRB2; NFE2L2; WNT7A; TP53; CYP2C9; NPPC; ESRRG; E2F1; DNMT1; ESR2; CYP3A4; SLC5A7; CYP2D6; BDNF; NR1H4; AR; CYP2C19 2025-04-02 Dinutuximab Y Y N N 2015 N DB09077 L01XC16 CHEMBL3137342 High Risk Neuroblastoma MYCN 2024-02-07 Docetaxel Y Y N Y 1996 Y DB01248 L01CD02 CHEMBL92 Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3 2024-07-24 Dostarlimab Y Y N N 2021 N DB15627 L01FF07 CHEMBL4298124 Adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen MSH6; MLH1; PDCD1 2025-04-02 Doxorubicin N Y Y Y 1974 Y DB00997 L01DB01 CHEMBL53463 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma BRCA1; BAZ2B; DOK5; CPT1A; FCGR2A; ERCC1; RXRA; GABPA; CYBA; SETD4; MSH2; RALBP1; BDNF; GSR; ATM; FASLG; PNPLA3; APEX1; XDH; TOP2A; GSTM3; SLC22A17; GSTM1; HSP90AA1; RPSA; UGT1A1; PAX8; CAST; PIK3CG; AKR7A2; CCND1; RARA; BIRC5; SLCO4C1; HSP90AB1; NTRK2; MAPT; TGM2; POLH; G6PD; ABCC5; GADD45A; PIK3CA; POLK; SRC; CYP2C19; MGMT; CYP3A4; GBX2; FCGR3A; CLCN6; NQO1; EDN1; IDH1; ZEB1; TOP1; SLCO1B1; ABCC4; SNCA; ABCG2; ERCC2; AR; AFP; KMT2A; SLC13A3; TOP2B; POLB; H2AX; KLC3; RECQL; AKR1C3; ABCC9; BRAF; PIK3CB; TET2; FLT3; EHMT2; NT5E; MAPK1; MTR; CBR1; GPX3; CYP2J2; GATA3; CYP1A2; NR1I2; BAX; GSTA2; THRB; TAF1; ATXN2; NR1H4; TPMT; CYP2C9; SMAD3; GALNT14; SERPINA6; FANCD2; SLCO6A1; PPARD; IL11; ABCB11; USP1; XIAP; SOD2; SLC15A1; STAT6; ESR1; KRT20; CDKN1B; LRP1B; ALK; CYP1A1; XPC; CYP1B1; MYOD1; DNMT3A; SP3; FCGR3B; NFE2L2; ABCB1; ALDH3A1; ABCC10; MTHFD1; IGHMBP2; CASP3; WRN; XRCC1; ABCA1; TGFB1; BLM; CYP3A; LINC00251; APAF1; SDHB; PPM1D; PLG; ABCC3; CYP2D6; BMP7; TP53; YWHAG; MYB; S100A4; SLC22A7; COL1A2; MAPK14; BCL2 2025-04-02 Doxorubicin Liposome Y Y N N 1998 Y Not found in DrugBank L01DB01 CHEMBL53463 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma BRCA1; BAZ2B; DOK5; CPT1A; FCGR2A; ERCC1; RXRA; GABPA; CYBA; SETD4; MSH2; RALBP1; BDNF; GSR; ATM; FASLG; PNPLA3; APEX1; XDH; TOP2A; GSTM3; SLC22A17; GSTM1; HSP90AA1; RPSA; UGT1A1; PAX8; CAST; PIK3CG; AKR7A2; CCND1; RARA; BIRC5; SLCO4C1; HSP90AB1; NTRK2; MAPT; TGM2; POLH; G6PD; ABCC5; GADD45A; PIK3CA; POLK; SRC; CYP2C19; MGMT; CYP3A4; GBX2; FCGR3A; CLCN6; NQO1; EDN1; IDH1; ZEB1; TOP1; SLCO1B1; ABCC4; SNCA; ABCG2; ERCC2; AR; AFP; KMT2A; SLC13A3; TOP2B; POLB; H2AX; KLC3; RECQL; AKR1C3; ABCC9; BRAF; PIK3CB; TET2; FLT3; EHMT2; NT5E; MAPK1; MTR; CBR1; GPX3; CYP2J2; GATA3; CYP1A2; NR1I2; BAX; GSTA2; THRB; TAF1; ATXN2; NR1H4; TPMT; CYP2C9; SMAD3; GALNT14; SERPINA6; FANCD2; SLCO6A1; PPARD; IL11; ABCB11; USP1; XIAP; SOD2; SLC15A1; STAT6; ESR1; KRT20; CDKN1B; LRP1B; ALK; CYP1A1; XPC; CYP1B1; MYOD1; DNMT3A; SP3; FCGR3B; NFE2L2; ABCB1; ALDH3A1; ABCC10; MTHFD1; IGHMBP2; CASP3; WRN; XRCC1; ABCA1; TGFB1; BLM; CYP3A; LINC00251; APAF1; SDHB; PPM1D; PLG; ABCC3; CYP2D6; BMP7; TP53; YWHAG; MYB; S100A4; SLC22A7; COL1A2; MAPK14; BCL2 2025-04-02 Durvalumab Y Y N N 2017 N DB11714 L01FF03 CHEMBL3301587 Unresectable Stage III Non-small Cell Lung Cancer; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC) ATM; CD274; IDH1; MSH2; MSH6; EGFR; PBRM1; ALK; PDCD1; MLH1 2025-04-02 Duvelisib Y Y N N 2018 N DB11952 L01EM04 CHEMBL3039502 Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma PIK3CG; PIK3CD; F5; TP53; F7; F7R; PIK3CB 2025-04-02 Edotreotide Y N N N 2019 N DB15494 V09IX09 CHEMBL408350 Neuroendocrine Tumors FASLG 2024-07-24 Eflornithine N Y N Y 2023 N DB06243 L01XX79 CHEMBL830 High Risk Neuroblastoma SMOX; MYCN; EHMT2; ATF2; ODC1; JUN; PRL; NR5A1; TGM2; KCNA1; XIAP 2025-04-02 Elacestrant Y Y N N 2023 N DB06374 L02BA04 CHEMBL4297509 Advanced Breast Cancer, Metastatic Breast Cancer ESR1; ERBB2 2024-07-24 Elotuzumab Y Y N N 2015 N DB06317 L01FX08 CHEMBL1743010 Refractory Multiple Myeloma GPR27; SLAMF7 2024-07-24 Elranatamab Y Y N N 2023 N DB15395 L01FX32 CHEMBL4297809 Relapsed or Refractory Multiple Myeloma CD3G; CD3E; TNFRSF17; CD3D 2025-04-02 Emapalumab N Y N N 2018 N DB14724 L04AA39 CHEMBL3989977 STX11; UNC13D; SH2D1A; RAB27A; IFNG; PRF1; XIAP; STXBP2 2025-04-02 Enasidenib N Y N N 2017 N DB13874 L01XX59 CHEMBL3989908 Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML) IDH2; IDH1; GRB2; FLT3 2025-04-02 Encorafenib Y Y N N 2018 N DB11718 L01EC03 CHEMBL3301612 Metastatic Melanoma; Unresectable Melanoma RAF1; PTEN; ARAF; NRAS; MAP2K1; KRAS; TP53; HRAS; BRAF 2025-04-02 Enfortumab Vedotin Y Y N N 2021 N DB13007 L01FX13 CHEMBL3301589 Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer TUBB2A; NECTIN4; TUBB1; TUBA3C; TUBB4B; HLA-DOB; TUBA1B; TUBB3; TUBB8; TUBB6; TUBB4A; TUBA3E; TUBA4A; TUBB; TUBA1C; TUBA1A; TUBB2B 2025-04-02 Ensartinib N Y N N 2024 N DB14860 CHEMBL4113131 ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) HBEGF; DRD4 2025-04-02 Entrectinib Y Y N N 2019 N DB11986 L01EX14 CHEMBL1983268 Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid FLT1; ALK; AXL; NTRK1; MAP4K2; PTK2; RPS6KA3; KDR; FGFR3; FYN; NTRK2; MET; PRKCQ; CAMK1D; FGFR1; FRK; CSF1R; SRC; GRK5; TBK1; LTK; RET; AURKA; TNK2; CDK7; DAPK3; JAK3; PRKCG; JAK2; TAOK1; MST1R; PRKAA1; BLK; BTK; EML4; SYK; PLK4; MAP4K5; STK3; FLT3; FLT4; HIPK2; LYN; SLK; CLK4; LRRK2; KIT; FER; MAP4K4; AURKB; NTRK3; ROS1; PKN2; ABL1; IGF1R; LCK; CLK2 2025-04-02 Enzalutamide Y Y N N 2012 N DB08899 L02BB04 CHEMBL1082407 Metastatic Castration Resistant Prostate Cancer TP53; PTEN; APC; TSC2; AR; TSC1; ATM; CYP17A1; BRAF; MLH1; PIK3CA; ATR; BEVI; CHEK2; BRCA2; RAD51C 2025-04-02 Epcoritamab Y Y N N 2023 N DB16672 L01FX27 CHEMBL4650393 Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL) CD3D; CD3G; CD3E; MS4A1 2024-07-24 Epirubicin N Y Y N 1999 Y DB00445 L01DB03 CHEMBL417 Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder EPHA6; TP53; TOP2A; SLC28A3; TP53AIP1; CHD1; BIRC5; BCL2; MDM4; SLCO1B1; PPP2R5D; TYMSOS; ERBB2; FOXP3; IGF2BP2; ABCC1; GNL3; SPIDR; TUBB2A; MISP; CBR3; INSR; PIK3R2; GCKR; KCNQ1; IRS1; HMMR; PERP; RBX1; ABCC2; ABCG2; NOS1; SERPINE1; FOXO1; ABCB1; CCNK 2025-04-02 Erdafitinib Y Y N N 2019 N DB12147 L01EN01 CHEMBL3545376 Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma FGFR2; FGFR4; DR1; TSC1; SLC26A3; PTEN; DRD2; DPYSL3; DPYSL2; PIK3CA; FGFR3; FGFR1; CYP2C9 2025-04-02 Eribulin Y Y N N 2010 Y DB08871 L01XX41 CHEMBL1683590 Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma ESR1; PGR; TUBB3; TUBB1; GCF1; TUBB2A; TERT; CYP3A4; TUBA4A; TUBA1A; TUBB4A; TUBB4B; CDK2; ERBB2; ESR2; TUBA1B; TUBB2B; TUBB; TUBB6; TUBA3C; TUBA3E; TUB; TUBA1C; TUBB8 2025-04-02 Erlotinib Y Y N Y 2004 Y DB00530 L01EB02 CHEMBL553 Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic EGFR; TP53; IGF1R; PTEN; ROS1; FRK; MET; CYP2D6; BLK; FGFR4; KRAS; HIPK4; SYK; CYP3A4; JAK2; ABCG2; PIK3CA; CYP1A2; PKN2; NF1; KDR; ABCB1; CLK4; RET; ERBB3; DVL2; BIRC5; LYN; UGT1A1; SLCO2B1; ABL1; NF2; APC; SLK; MKNK2; CBL; UHRF1; DDR2; MAP3K1; FLT4; BRAF; ALK; CYP3A5; MAPK1; MINK1; LTK; NUP62; FLT1; PRKD2; AR; DXO; ERBB4; ARF1; AURKB; YES1; ERBB2 2025-04-02 Estramustine N Y Y N 1981 N DB01196 L01XX11 CHEMBL1575 Metastatic Hormone Refractory Prostate Cancer KLK3; AR; BLM; BAX; POLK; TDP1; USP1; BCL2; HEXB; VDR; KAT2A 2025-04-02 Etoposide N Y Y Y 1983 Y DB00773 L01CB01 CHEMBL44657 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer TBP; AFP; GSTM1; HSPB2; UGT1A10; TOP2B; GLP1R; ALK; ABCC1; EIF4E; SF3B1; CYP1A2; DDIT3; BCL2; BTF3P11; CYP2D6; PGP; ATM; TOP2A; E2F1; NCOA3; BLMH; CYP2C19; YAP1; MAPK3; MYCN; IGF2; KLK3; BAX; NQO1; TYMS; SLIT1; NR4A1; SLCO1B1; SLC2A4; XIAP; DYNC2H1; ACTR2; ITGAL; ABCC3; PLA2G1B; MUC16; CHEK1; PLA2G6; TGFB1; MAPK1; CYP2C9; PAPOLA; TYMSOS; NCOA1; GBX2; TNFSF13B; FGFR1; TP53; GMNN; CYP3A4; GSTT1; GDF15 2025-04-02 Everolimus Y Y N N 2009 Y DB01590 L04AA18; L01EG02 CHEMBL1908360 Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors AKT3; MTOR; ESR1; ESR2; ATM; AKT1; AKT2; PIK3CA; PBRM1; FKBP1A; NF1; ETFB; ERBB2; PTEN; BAP1; FLT3; KRAS; TSC1; HRAS; AR; FLCN; PIK3R1; BRAF; KDM5C; RPTOR; STK11; RET; FGFR4; VHL; CDKN2A; TSC2; NF2; NRAS; CTNNB1 2025-04-02 Exemestane N Y Y N 1999 Y DB00990 L02BG06 CHEMBL1200374 Early Breast Cancer; Refractory, advanced Breast cancer BGLAP; CPD; AKR1C3; ESR2; TUBB1; IGF1R; MAP4K4; ERBB2; TCL1A; CCDC148; CYP19A1; CYP1B1; NFE2L2; ESR1; PGR; AR 2025-04-02 Fedratinib Y Y N N 2019 N DB12500 L01EJ02 CHEMBL1287853 JAK2; EPHB2; EPHB1; TYK2; EFNA4; EPHB3; FLT3 2025-04-02 Fludarabine N Y Y Y 1991 Y DB01073 L01BB05 CHEMBL1568 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma POLD3; RRM2; DCK; POLD1; RRM2B; GBA1LP; POLA1; PRIM2; POLE2; SMAD3; CD40; PRIM1; RRM1; ADH1A; CYP2E1; SULT2B1; POLD4; XIAP; MPO; SLC22A12; POLE; IKZF1; ADA; SLC29A1; NIPSNAP2; SLCO1B1; NFE2L2; POLE3; BAX; POLD2; PIK3CG; POLA2; ATM; CXCL12 2025-04-02 Fluorouracil N Y Y Y 1962 Y DB00544 L01BC02 CHEMBL185 Breast Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Rectal Carcinoma; Superficial Basal Cell Carcinoma LGR5; TMEM167A; GCKR; MTHFR; UPB1; BIRC5; CHN2; GNAS; TYMS; PIK3R2; MECP2; PERP; RALBP1; DPYD; DLG5; MLH1; HBB; SCN1A; WNT5B; CBR1; DTYMK; TYMSOS; NT5C1A; PTEN; CCND1; ATRX; IGFBP3; MEGF11; ABCG1; TSHB; IRS1; ABCC2; IL11; TYMP; TOP2A; CBR3; COLEC10; SELE; KLC1; CYP3A4; FAS; KCNQ1; CYP3A; PTPRC; CCNK; IL2RA; E2F1; CDKN1A; CYP4X1; OSGEP; NLGN1; MUC2; MYB; HMMR; TP53AIP1; ALCAM; PDGFRB; ABCC4; MSH6; REV3L; BAX; CDC25C; CXCL8; NRAS; CYP2C8; HSPA5; PARD3B; ERCC6; XRCC3; EXO1; ITGAL; RGS5; PSMB3P1; MAP2K1; ENOSF1; ERCC1; RBX1; ALDH3A1; CYP2C19; BRAF; FGFR4; SLC22A16; GALNT14; CYP19A1; ABCB1; NOS1; TP53; CYP2E1; CSPG4; IGF2BP2; INSR; FPGS; EGFR; MUTYH; ABCC5; GNL3; AURKA; OR10AE3P; ATM; FOXO1; DKK1; PIK3CA; SLC19A1; APEX1; SMAD4; PPP2R5D; CYP2A6; KLC3; TWIST1; CYP1B1; FGFR2; RAD51C; TPT1; IL6R; BDNF; ABCC1 2025-04-02 Fluoxymesterone N Y N N 1956 Y DB01185 G03BA01 CHEMBL1445 Inoperable, metastatic Breast cancer BEVI; AR; PRL; NR3C1 2025-04-02 Flutamide N Y Y N 1989 Y DB00499 L02BB01 CHEMBL806 C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma VIP; AR; EHMT2; BEVI; G6PD; RORC; KLK3; CYP3A4; NFE2L2; CYP2C9; CYP1A2; CDKN1A; BIRC5; CYP2C19; MPO; TH; NR1I2; AQP9; IL2RA; PEBP1 2025-04-02 Fotemustine Y N N N DB04106 L01AD05 CHEMBL549386 Metastatic Melanoma MGMT; TXNRD1 2024-02-07 Fruquintinib Y Y N N 2023 N DB11679 L01EK04 CHEMBL4303214 Metastatic Colorectal Cancer KDR; FLT4; DRD2; DRD1; KRAS; DRD3; FLT1 2025-04-02 Fulvestrant Y Y N N 2002 Y DB00947 L02BA03 CHEMBL1358 Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer ERBB2; ESR1; PGR; TFPI; FGFR2; CCNE1; PIK3CG; RB1; ESR2; FGF2; TP53; EML4; PIK3CA; CDK6; ALK; BCYRN1P2; NOS1; BDNF; AKT1; CYP1A2; ESRRA; XIAP; PTEN; ALDH3B1; EPHX2 2025-04-02 Futibatinib Y Y N N 2022 N DB15149 L01EN04 CHEMBL3701238 Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma FGFR3; FGFR2; BRAF; DPYSL3; DPYSL2; FGFR4; DR1; NRAS; SLC26A3; PIK3CA; FGFR1 2025-04-02 Gefitinib Y Y N Y 2003 Y DB00317 L01EB01 CHEMBL939 Metastatic Non-Small Cell Lung Cancer IRAK4; GMNN; ERBB3; PTEN; LYN; PIK3CA; HCK; IGF2; BLK; ERBB4; ABCB1; CAMK2D; MET; ARF1; CAMK2G; CYP2C9; MAP4K4; CYP3A5; SIRT2; CYP2D6; EGFR; PRKD2; MAPK8; DXO; SIK2; BRAF; FLT4; PRKD3; EMP1; PBK; PHKG2; CSNK1D; BRSK1; ALK; CHEK2; MKNK2; FRK; MAPK10; SMO; MINK1; FGFR3; MAPK14; UHRF1; PIM1; IGF1R; SLK; HIPK4; LCK; PLAU; NUP62; ERBB2; CEACAM5; TNK2; ROS1; RELA; KRAS; MAP4K5; YES1; MAPK9; LIMK1; IRAK1; CRKL; DVL2; MAP3K1; AXL; PIM3; MAPT 2025-04-02 Gemcitabine N Y Y Y 1996 Y DB00441 L01BC05 CHEMBL888 Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma KLC3; KRAS; POLE3; AR; PRIM1; POLR1G; TENT4A; RRM1; PPCDC; FGFR2; ATAT1; NIPSNAP2; CDA; IGF2; ETS2; RRM2; NT5C1A; OR4D6; SMAD4; MS4A2; CYP2C8; CHEK1; SLC29A1; MSH5; POLD1; PPP1R18; BTRC; FHL2; FKBP5; PPP1R13L; PSORS1C1; GPX5; CBL; MUCL3; SH2D5; SERPINC1; WEE1; MTHFR; NT5C; ALG10; DCP1B; PRIM2; HRAS; PRB2; XYLT2; DDX53; BAZ2B; XRCC1; POLE; TGM2; ACSS2; POLE2; RRM2B; CDKN2A; CDC5L; CDSN; POLD3; GBA1LP; CAMK4; ERBB2; NRAS; HLA-C; TNC; SLCO1B1; BRCA2; MTHFD1; DOCK8; C6orf15; POLA2; ALOX5AP; WWOX; PIK3CA; NRG1; PTEN; POLD2; TP53; PRRC2A; RAF1; FGFR3; BRAF; BRCA1; POLA1; POLD4; SLC29A2; ERCC1; SERPINA5; CIP2A; ESR2; HCP5; UBASH3B; TNF; FANCC 2025-04-02 Gemtuzumab Ozogamicin Y Y N N 2000 N DB00056 L01FX02 CHEMBL1201506 Acute Myeloid Leukemia (AML); Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML) ADH1A; CHEK1; SULT2B1; CYP2E1; ABCB1; SLCO1B1; SLC22A12; GAPDHP60; CD33 2025-04-02 Gilteritinib Y Y N N 2018 N DB12141 L01EX13 CHEMBL3301622 Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations AXL; FLT3; KIT; ALK; DTNB; NRAS; DRD5P1; DTNA; IDH2; JAK2; HBEGF; DTX1; BRAF; JAK3; CBL; PTK2B; EML4; DPYS 2025-04-02 Glasdegib Y Y N N 2018 N DB11978 L01XJ03 CHEMBL2043437 Acute Myeloid Leukemia (AML) FLT3; SMO; MTOR; ALOX12 2025-04-02 Glofitamab Y Y N N 2023 N DB16371 L01FX28 CHEMBL4298092 Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified CD3E; CD3G; MS4A1; CD3D 2025-04-02 Goserelin N Y Y N 1989 N DB00014 L02AE03 CHEMBL1201247 Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR 2024-07-24 Histamine dihydrochloride Y Y N N 1939 N DB05381 L03AX14 CHEMBL90 Acute Myeloid Leukaemia HRH3; EHMT2; GAPDH; HRH4; GLUD1P3; HRH2; USP1; AMD1; UBE2K; LMNA; AMELX; HRH1; SLC29A4 2025-04-02 Histrelin N Y N N 1991 N DB06788 L02AE05 CHEMBL1201255 Advanced Prostate Cancer GNRHR2; GNRHR 2025-04-02 Hydroxyurea N Y N N 1967 Y DB01005 L01XX05 CHEMBL467 Essential Thrombocythemia (ET); Head and Neck Carcinoma; Melanomas; Ovarian Cancer Metastatic; Polycythemia Vera (PV); Chronic, refractory Myeloid Leukemia; Inoperable Ovarian cancer BLM; EIF4E; HRAS; GBA1LP; CYP3A4; DNMT1; MAP3K5; RRM1; ABL1; ASS1; RRM2B; PTH; NIPSNAP2; DNTT; TET2; SIN3A; CP; RRM2; KLF4; JAK2; DUSP1 2025-04-02 Ibritumomab Tiuxetan Y Y N N 2002 N DB00078 V10XX02 CHEMBL1201606 Follicular Non-Hodgkin's Lymphoma; Follicular Non-Hodgkin's Lymphoma Refractory MS4A1; GATM 2025-04-02 Ibrutinib Y Y N N 2013 N DB09053 L01EL01 CHEMBL1873475 Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM) TP53; ENUR2; CYP2D6; ATM; EFNA1; SMAD3; EFNB2; TEC; EGFR; ENO2; FKBP1AP3; PIM1; ERBB2; FGR; MYC; EPHX2; DXO; YES1; ERBB4; CSF3R; SMARCA4; FLT3; EEGV1; EN1; MS4A2; EPHA8; BLK; PLCG2; EPHB3; EPS15; LYN; BMX; MYD88; BTK 2025-04-02 Idarubicin N Y Y N 1990 Y DB01177 L01DB06 CHEMBL1117 Acute Myeloid Leukemia (AML) APEX1; TOP2A; THRB; IDH1; CBX1; SLC22A12; ABCB1; POLK; RECQL; ETV6; POLH; USP1; RAPGEF3; CYP2E1; POLI; DNMT3A; ATXN2; FEN1; ERG; PPARD; DRD1; MTOR; NT5C3A; DCK; CYBA; KCNH2; AR; PLK1; WRN; POLB; RAC2; ADH1A; EHMT2; MPHOSPH8; RAPGEF4; CBR3; MAPT; NQO1; FLT3; ATAD5; BLM; quinone dehydrogenase 2; CSF2; SULT2B1; BRD10; SLCO1B1; HTT; NCF4 2025-04-02 Idecabtagene Vicleucel Y Y N N 2021 N DB16665 L01XL07 CHEMBL4298199 Refractory Multiple Myeloma, Relapsed Multiple Myeloma TNFRSF17 2024-02-07 Idelalisib Y Y N N 2014 N DB09054 L01EM01 CHEMBL2216870 Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma PIK3CB; TP53; BRAF; PIK3CD; PTEN; F5; F7; PIK3CA; F7R 2025-04-02 Ifosfamide N Y Y Y 1988 Y DB01181 L01AA06 CHEMBL1024 Cancer, Bladder; Cervical Cancers; Ewing's Sarcoma; Head and Neck Carcinoma; Lymphoma, Hodgkins; Malignant Neoplasm of Pancreas; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Testicular Germ Cell Cancer; Advanced thymic carcinoma DNMT1; KLC3; CYP2B6; IL6; ALDH1A1; TP53; CYP2A6; MGMT; ERCC2; GSTP1; TERC; ALK; NR1I2; HSPA4 2025-04-02 Imatinib Y Y N Y 2001 Y DB00619 L01EA01 CHEMBL941 Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor PDGFRB; PDGFRA; CYP2B6; SLC19A1; CLK4; NF1; ABL1; CTNNB1; NTRK1; UGT2A1; quinone dehydrogenase 2; BCR; XIAP; CYP3A5; ATIC; DDR1; BCL2L11; FLT3; FGF2; SLC2A4; CYP2F1; ABCA3; HGF; DUSP2; RAD52; KRAS; BIRC5; PDGFB; ALK; PRKCH; DUSP1; ABCC4; YES1; ABI1; EYA2; RET; MAPK10; FIP1L1; CSF3R; IDH1; ULK3; ABCB4; NF2; LYN; ABCG2; JAK2; LCK; RUNDC3B; GSTT1; HCK; CHST1; TAOK1; PTEN; SMAD3; PVT1; SLCO1A2; IRAK1; CYP3A4; EGFR; IKZF1; CSF1R; SFN; CD40LG; ARID5B; ABCB1; BRAF; KIT; PIK3CG; RUNX1; FRK; MYC; SYK 2025-04-02 Imiquimod Y Y N N 1997 Y DB00724 D06BB10 CHEMBL1282 Superficial Basal Cell Carcinoma GMNN; SARDH; TLR7; IFNA1 2025-04-02 Inavolisib N Y N N 2024 DB15275 CHEMBL4650215 Locally advanced or metastatic breast cancer PIK3CB; F7; F5; F7R 2025-04-02 Infigratinib N Y N N 2021 N DB11886 L01EN03 CHEMBL1852688 Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas FGFR2; FGFR3; PIK3C2B; PIK3CA; PIK3CG; PIK3R4; FGFR1; PIK3R5; DR1; KIT; FGFR4; PIK3R3; PIK3C2G; MTOR; PIK3CD; PIK3R6; PTEN; NRAS; DPYSL3; DRD2; DPYSL2; PIK3R1; PIK3C3; PIK3R2; SLC26A3; PIK3CB; PIK3C2A 2025-04-02 Inotuzumab Ozogamicin Y Y N N 2017 N DB05889 L01FB01 CHEMBL2108611 Refractory B-cell precursor acute lymphoblastic leukemia; Relapsed B cell precursor Acute lymphoblastic leukemia CD22; BCR; ABL1; GNG4 2025-04-02 Interferon Alfa-2b Y Y N N 1986 N DB00105 L03AB05 CHEMBL1201558 Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant CSF2; TGFB1; IFNAR2; IFNA2; ITPA; FTO; BAX; IL6; IFNAR1; IFNL4; IFNG; TP53; IL18; EIF2AK2 2025-04-02 Iobenguane I-131 N Y N N 1994 N DB06704 V09IX01; V09IX02; V10XA02 CHEMBL1615779 Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas TH; SLC6A2 2025-04-02 Ipilimumab Y Y N N 2011 N DB06186 L01FX04 CHEMBL1789844 Advanced Renal Cell Carcinoma; Cutaneous Melanoma; Hepatocellular Carcinoma; Metastatic Melanoma; Unresectable Melanoma; Metastatic MSI-H/dMMR colorectal cancer MLH1; CTLA4; HLA-A; PBRM1; TP53; MSH6; MDM2; CD274; GLRB; EGFR; ATM; PTEN; ALK; BRAF; NRAS 2025-04-02 Irinotecan N Y Y Y 1996 Y DB00762 L01CE02 CHEMBL481 Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma NRAS; KLC1; ABCC5; NAT2; DCBLD1; BCHE; MAP2K1; PIK3CA; UBE2I; CES1; PLCB1; ERBB2; UGT1A1; MAPK10; CDKN1A; RAD50; RALBP1; TP53; KCNQ5; DKK1; TGFB1; ABCC1; RGS5; C8orf34; PDGFRB; RUNX3; E2F1; SLCO1B3; TYMSOS; ISG15; MGMT; CES2; TGFBR2; UGT1A; SHMT1; TDP1; XRCC3; PDZRN3; TSC2; UGT1A8; GSTP1; KRAS; ALK; AREG; AR; FGFR3; TYMS; BRAF; TOP1; CSPG4; ABCC4; SLC19A1; GSTM1; SYNE3; BIRC5; MTHFR; HSD17B10; PIN1; SEMA3C; ABCG1; ATM; TOP1MT; UGT1A10 2025-04-02 Irinotecan Liposome Y Y N N 1996 Y DB00762 L01XX19 CHEMBL481 Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma NRAS; KLC1; ABCC5; NAT2; DCBLD1; BCHE; MAP2K1; PIK3CA; UBE2I; CES1; PLCB1; ERBB2; UGT1A1; MAPK10; CDKN1A; RAD50; RALBP1; TP53; KCNQ5; DKK1; TGFB1; ABCC1; RGS5; C8orf34; PDGFRB; RUNX3; E2F1; SLCO1B3; TYMSOS; ISG15; MGMT; CES2; TGFBR2; UGT1A; SHMT1; TDP1; XRCC3; PDZRN3; TSC2; UGT1A8; GSTP1; KRAS; ALK; AREG; AR; FGFR3; TYMS; BRAF; TOP1; CSPG4; ABCC4; SLC19A1; GSTM1; SYNE3; BIRC5; MTHFR; HSD17B10; PIN1; SEMA3C; ABCG1; ATM; TOP1MT; UGT1A10 2025-04-02 Isatuximab Y Y N N 2020 N DB14811 L01FC02 CHEMBL3545131 Multiple Myeloma (MM) GMPR 2024-07-24 Ivosidenib Y Y N N 2018 N DB14568 L01XX62 CHEMBL3989958 Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation IDH1; GPX1P2; IDH2 2025-04-02 Ixabepilone N Y N N 2007 N DB04845 L01DC04 CHEMBL1201752 Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer TUBA3E; TUBB4A; TUBB1; TUBB6; TUBB3; CYP3A4; ESR1; PGR; TUBA1B; GCF1; TUBB4B; TUBA3C; TUB; TUBB2A; TUBB8; TUBB; TUBB2B; TUBA1C; ESR2; TUBA4A; TUBA1A; ERBB2 2025-04-02 Ixazomib Y Y N N 2015 N DB09570 L01XG03 CHEMBL2141296 Multiple Myeloma (MM) PSMB3; PSMD12; PSMA7; PSMC6; PSMC1; EML4; PSMB4; PSMB10; ADRM1; PSMD4; PSMD2; PSMD6; PSMA2; PSMD1; PSMA4; PSMA6; SEM1; PSMB7; PSMD13; PSMD8; PSMC4; PSMB5; PSMA3; PSMB11; PSMB1; PSMD3; PSMB2; PSMC3; ALK; TP53; PSMC5; FRA6F; PSMD11; PSMD7; PSMA8; PSMB6; PSMA1; PSMA5; PSMB9; PSMC2; PSMB8; PSMD14 2025-04-02 Lanreotide N Y Y N 2007 Y DB06791 H01CB03 CHEMBL1201185 Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG 2024-07-25 Lapatinib Y Y N N 2007 Y DB01259 L01EH01 CHEMBL554 Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer ERBB4; EGFR; HLA-DRB1; ERBB2; ERBB3; HLA-A; DXO; ESR2; NF2; EN1; KRAS; NRG1; HLA-C; EEF2K; PIK3CA; RET; CYP3A4; CDKN1B; CCND1; ESR1; HLA-B; ABCB11; CYP3A5; BRAF; YES1; MET; BIRC5; AURKB; HLA-DQA1; PTEN; PGR 2025-04-02 Larotrectinib Y Y N N 2018 N DB14723 L01EX12 CHEMBL3889654 NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive NTRK3; NTRK1; DRD5P1; NTRK2 2025-04-02 Lazertinib Y Y N N 2024 DB16216 L01EB09 CHEMBL4558324 First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) DRD2; DXO; FDX1; EGFR; EPHB3 2025-04-02 Lenalidomide Y Y N Y 2005 Y DB00480 L04AX04 CHEMBL848 Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma CRBN; DDB1; RBX1; CTNNB1; VEGFA; KDR; FGF2; TNFSF11; VEGFB; VEGFC; TP53; TNF; CUL4A 2025-04-02 Lenvatinib Y Y N N 2015 N DB09078 L01EX08 CHEMBL1289601 Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer FLT4; CYP3A4; FGFR2; FLT1; NRAS; BRAF; FGFR1; YES1; KDR; DRD3; PDGFRB; EGFR; KIT; CYP3A; ABCG2; PDGFRA; RET; CYP3A5; DRD2 2025-04-02 Letrozole N Y Y N 1997 Y DB01006 L02BG04 CHEMBL1444 Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer PGR; CCDC148; ESR1; CYP3A4; ERBB2; ZNF613; CYP19A1; PIK3CA; CYP2A6; CYP1B1; PTEN; CPD; CTNNB1; KIT; RB1; CDKN2A; SFTPA1; MMP2 2025-04-02 Leuprolide N Y N N 1985 Y DB00007 L02AE51; L02AE02 CHEMBL1201199 Advanced Prostate Cancer GNRHR; CYP2C19; CYP3A4; CYP2D6; CYP1A2; GNRH1; MMP1; CYP2C9; SMAD3; AR 2025-04-02 Lifileucel N Y N N 2024 N DB17107 L01XL11 CHEMBL4298200 Unresectable or metastatic melanoma 2024-04-24 Lisocabtagene Maraleucel Y Y N N 2021 N DB16582 L01XL08 CHEMBL4297236 Grade 3b Follicular Lymphoma; High-grade B-cell Lymphoma (HGBCL); Primary mediastinal large B-cell lymphomas; Refractory Diffuse Large B Cell Lymphoma; Refractory Large B-cell Lymphoma; Relapsed Large B-cell Lymphoma; Relapsed, Diffuse Large B-cell Lymphoma, Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) CD19 2024-07-31 Lomustine N Y Y N 1976 N DB01206 L01AD02 CHEMBL514 Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain MGMT; EGFR; ADK; IDH1 2025-04-02 Loncastuximab Tesirine Y Y N N 2021 N DB16222 L01FX22 CHEMBL4297778 Refractory Large B-cell Lymphoma, Relapsed Large B-cell Lymphoma GMFB 2025-04-02 Lorlatinib Y Y N N 2018 N DB12130 L01ED05 CHEMBL3286830 Progressive, metastatic Anaplastic lymphoma kinase-positive Metastatic Non-Small Cell Lung Cancer DTX1; HRAS; ALK; ROS1; FGFR1; EML4; TP53; PIK3CA; ENO1; NRAS; BRAF; HBEGF; RB1 2025-04-02 Lu 177-Dotatate Y Y N N 2018 N DB13985 V10XX04 CHEMBL3989924 Gastroenteropancreatic Neuroendocrine Tumors SSTR1; SSTR5; SSTR3; SSTR2; SSTR4 2024-07-24 Lurbinectedin N Y N N 2020 N DB12674 L01XX69 CHEMBL4297516 Metastatic Small Cell Lung Cancer 2020-09-17 Lutetium Lu 177 Vipivotide Tetraxetan Y Y N N 2022 N DB16778 V10XX05 CHEMBL4594406 Metastatic Castration Resistant Prostate Cancer (CRPC) FOLH1 2024-02-07 Margetuximab N Y N N 2020 N DB14967 L01FD06 CHEMBL2364649 HER2-positive Metastatic Breast Cancer EN1 2024-07-24 Mechlorethamine Y Y N N 1949 N DB00888 L01AA05 CHEMBL427 Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion XRCC1; MMP2; MT-CO1; BAX; CSF2; ERBB2; GSTP1; TSHB; NOS1; CXCR2; GSR 2025-04-02 Medroxyprogesterone N Y Y N 1959 Y DB00603 G03DA02; G03AC06; L02AB02 CHEMBL717 Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma CYP1B1; MMP1; CYP3A5; PGR; ESR1; VDR; BAX 2025-04-02 Megestrol Acetate N Y Y N 1971 Y DB00351 G03DB02; G03AC05; L02AB01 CHEMBL1201139 Advanced Breast Cancer; Advanced Endometrial Cancer ESR1; PGR 2025-04-02 Melphalan N Y Y Y 1964 Y DB01042 L01AA03 CHEMBL852 Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma NR1H4; SLC7A5; AR; ABL1; GSTP1; POLR1G; ABCC1; PLAT; CTLA4; CYP3A4; IFNG; RORC; CDKN1A; TP53; MGMT; EHMT2; OPLAH; FANCC; ABCB1; NFE2L2 2025-04-02 Melphalan Flufenamide Y Y N N 2021 N DB16627 L01AA10 CHEMBL4303060 Relapsed Or Refractory Multiple Myeloma NR1H4; SLC7A5; AR; ABL1; GSTP1; POLR1G; ABCC1; PLAT; CTLA4; CYP3A4; IFNG; RORC; CDKN1A; TP53; MGMT; EHMT2; OPLAH; FANCC; ABCB1; NFE2L2 2025-04-02 Mercaptopurine Y Y N Y 1953 Y DB01033 L01BB02 CHEMBL1425 Acute Lymphoblastic Leukaemias (ALL); Acute Promyelocytic Leukemia (APL); Lymphoma, Lymphoblastic SLC22A1; CYP2A7; NT5C2; CYP2C19; XDH; SLC28A3; COMT; CYP1A2; NUDT15; IGHMBP2; FOLH1; KDM4E; SLC28A2; SLC29A2; KDM4A; TYMSOS; CNNM2; IMPDH1; MTHFR; ALDH1A1; HBB; TDP1; TP53; CPT1A; HLA-DQA1; PRPS1; VCAM1; UGT1A1; SLC29A1; NFE2L2; CYP2D6; BAZ2B; IDH1; CYP2C9; TPMT; GSTP1; IL2RA; FTO; HPRT1; PPAT; GNMT; CYP3A4; PNPLA3; HLA-DRB1; GATA3 2025-04-02 Methotrexate Y Y N Y 1953 Y DB00563 L04AX03; L01BA01 CHEMBL34259 Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer FLT3; NFE2L2; SOD2; NCOA3; SLC22A11; ATF5; DHFR; FTCDNL1; MIR3117; CLTC; GATA3; FOLH1; SLC16A7; MSH3; GSTT1; POLH; CYP2C19; COL18A1; SLC46A1; KIR2DS4; AFP; S100A8; SLAMF1; HLA-E; LINC00251; GSK3B; BMP7; FGF14; CDH16; ABCC4; AHRR; POLB; SLC29A1; HSD17B10; IL1RN; CPT1A; ADA; MPHOSPH8; IL2; APEX1; CDKN1B; SLC22A8; POLI; CYP1A2; SLC19A1; SLC22A9; SULT2A1; TP53; IMPDH1; NQO1; NTRK1; ALK; HGF; NR3C1; TLR4; S100A12; PYGL; HLA-C; E2F1; BAX; NOS3; MIR4268; ENG; CYP3A4; IDH1; PFDN4; FGFR4; NALCN; VDR; PPARG; NOP2; CDK9; BCOR; ATIC; CDH2; ENOSF1; ICAM3; GLS; CYP2D6; CCND1; ALOX5; NFATC2; FCGR3B; SPECC1L; EHMT2; IKZF1; RBMS3; KLC3; ATP5F1E; TYMS; SLC28A3; PNPLA3; NFATC1; TAT; FOXP3; FOLR1; KCNA1; IGHMBP2; GSTM1; SLCO1B1; TNFAIP3; HSPB2; BIRC5; ERCC2; TPM3; DOK5; CYP2C9; NR1I2; KLRD1; CYP2B6 2025-04-02 Midostaurin Y Y N N 2017 N DB06595 L01EX10 CHEMBL608533 Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm PRKCD; KIT; PRKD3; PRKD1; DPYS; NPM1; TNF; FGFR3; PIK3CB; NTRK3; PDGFRA; KDR; PRKCZ; IDH2; IL6; PRKCI; PRKCB; FGFR1; PRKCG; YES1; PDGFRB; CBL; PRKCE; STK32B; JAK3; IL2; HSPA4; PIK3CA; PRKCQ; PRKCA; CTSV; PRKCH; FLT3; JAK2; LATS2 2025-04-02 Mifamurtide Y N N N 2009 N DB13615 L03AX15 CHEMBL2107354 High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma NOD2 2024-02-07 Mirvetuximab Soravtansine Y Y N N 2022 N DB12489 L01FX26 CHEMBL3545132 Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer FOLR1; TUBB6; TUBA4A; TUBB1; TUBA3C; TUBB4B; TUBB; TUBA3E; TUBB2A; TUBA1B; TUBB4A; TUBA1C; TUBB2B; TUBB3; TUBB8; TUBA1A 2025-04-02 Mitomycin N Y Y N 1981 Y DB00305 L01DC03 CHEMBL105 Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC) MAPK10; BGLAP; KRT18; FANCC; VWF; CYP1A2; IL1A; CYP7B1; TP53; BRCA1; ABCB4; AR; ABCB1; CYP2C9; PALB2; LGALS2; CYP2D6; XDH; CYP3A4; CGB5; CYP2C19; TAT; DHFR; TYMS 2025-04-02 Mitoxantrone N Y Y N 1987 Y DB01204 L01DB07 CHEMBL58 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma MBNL1; BAX; CBX1; WRN; SLCO1B1; KDM4A; ABCB1; DCK; MPHOSPH8; MECP2; YES1; GALNT14; ARSA; POLI; POLH; NFKB1; UGT1A5; DNMT1; ATAD5; EHMT2; RGS4; POLK; BRCA1; BCL2; HTT; TP53; PIM1; SMAD3; BLM; C10orf67; CYP3A4; GBX2; FEN1; THPO; NSD2; RACGAP1; ATXN2; FLT3; RECQL; RAD52; RPSA; MAPK1; ABCG2; TOP2A 2025-04-02 Mobocertinib N Y N N 2021 N DB16390 L01EB10 CHEMBL4650319 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer DXO 2025-04-02 Mogamulizumab Y Y N N 2018 N DB12498 L01FX09 CHEMBL1743041 Refractory Mycosis Fungoides/Sezary Syndrome; Relapsed Mycosis Fungoides/Sezary Syndrome CCR4 2025-04-02 Mosunetuzumab Y N N N 2022 N DB15434 L01FX25 CHEMBL4297788 Relapsed follicular lymphoma, Refractory follicular lymphoma GATM; GLRA2 2025-04-02 Moxetumomab Pasudotox Y Y N N 2018 N DB12688 L01FB02 CHEMBL1743043 Relapsed/Refractory Hairy Cell Leukemia CD22; EEF2; GNG4 2025-04-02 Nab-Paclitaxel Y Y N N 2005 Y Not found in DrugBank L01CD01 CHEMBL428647 Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer TUBA4A; TP53; MSH6; SLCO1B3; BCL2; EPHA5; ARHGEF10; CDKN2A; GSTM1; PGP; GSTT1; NRG3; RAF1; TUBB; CHEK1; MLH1; FNTB; BRCA1; ERBB2; GCF1; RRM1; NOP2; TUBB4A; PTEN; TUBA1B; TUBA3C; MISP; HRAS; CDK2; ABCG2; FOS; CYP3A; FGD4; TUBB2B; ERCC2; AR; CASP3; EPHA6; RB1; MAP3K1; ASS1; ABCC1; SLC29A1; TUBB8; TUBA3E; SLCO1B1; NFE2; NAT2; ABCC2; SYK; SOD2; TUBB1; CYP3A5; ETS2; EIF4E2; TUBB2A; TIGD1; LIG3; EIF4EBP1; EGFR; ACSS2; PIK3CG; FCGR2A; ROS1; CDKN1A; BIRC5; JAK2; SPIDR; MYB; CBR3; DSCAM; BDNF; E2F1; FZD3; TLE3; KRAS; AURKA; NRG1; TRIM5; NR1I2; TUBA1C; AFG2A; ABCC10; CXCL8; MMP2; IL2RA; STMN1; TUBB6; ATM; PIK3CA; RAD51C; ERCC1; MAD1L1; ABCB1; FASN; EMSY; TUBA1A; LIF; TUBB4B; GMNN; FGFR1; NBEAP1; ABCC3; DDIT3; PDCD4; TOP2A; GSTP1; EDNRB; TUBB3; TUBA3D 2025-04-02 Nab-Sirolimus N Y N N 2021 Y DB00877 L04AH01 CHEMBL413 Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) MTOR; PIM1; EGFR; EIF4E; FLCN; ABCG2; FGFR1; FKBP1A; AR; NFE2L2; BAX; IL10; HRAS; TGM2; ALK; PTEN; IL17A; MAPK10; RPS6KB1; FKBP4; TCF7L2; NR1I2; WT1; PIK3CA; RBL2; IGFBP1; OPRK1; ADAMTSL4-AS1; IL15; NF1; NRAS; PRKAA1; PLAU; CTLA4; MMP1; TP53; CRLF2; PGR; GAPDHP67; RHEB; TSC1; IL7; DDIT3; CDKN2A; APC; RB1; ABCB1; NOS1; FGF2; ITGAL; JAK2; EML4; DCN; TSC2; FBXW7; ERBB2; RPTOR; DDC 2025-04-02 Nadofaragene Firadenovec N Y N N 2022 N DB17381 L01XL10 CHEMBL3990041 High risk BCG-unresponsive non-muscle invasive bladder cancer IFNA2 2024-02-07 Naxitamab N Y N N 2020 N DB15965 L01FX21 CHEMBL4297984 High risk, refractory Neuroblastomas of the bone or bone marrow; High risk, relapsed Neuroblastomas of the bone or bone marrow 2022-10-23 Necitumumab Y Y N N 2015 N DB09559 L01FE03 CHEMBL1743047 Metastatic Non-Small Cell Lung Cancer DXO; EGFR 2025-04-02 Nelarabine Y Y N N 2005 Y DB01280 L01BB07 CHEMBL1201112 Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia POLA1 2025-04-02 Neratinib Y Y N N 2017 N DB11828 L01EH02 CHEMBL180022 Breast Cancer EGFR; PIK3CA; ESR2; ERBB4; KDR; ESR1; BRAF; DXO; ERBB2; PTEN; HERC2; PGR; EN1; CBL; YES1 2025-04-02 Nilotinib Y Y N Y 2007 N DB04868 L01EA03 CHEMBL255863 Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia UGT1A1; DUSP1; NF1; KIT; PDGFRA; BCR; GSTP1; CYP1A1; FLT3; ABCG2; DUSP2; DDR2; ABI1; ABL1; PDGFRB; CYP3A4 2025-04-02 Nilutamide N Y N N 1996 Y DB00665 L02BB02 CHEMBL1274 Metastatic Hormone Refractory Prostate Cancer AR; KLK3; CYP2C19; CYP1A2; BEVI; CYP3A4; CYP2D6; PRL; CYP2C9; NFE2L2 2025-04-02 Nintedanib Y Y N N 2014 Y DB09079 L01EX09 CHEMBL502835 Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma DPYSL3; CFLAR; FGFR1; FGFR3; KIT; DR1; SLC26A3; DPP4; RET; DRD1; PIK3CA; FGFR2; DPP6; DPYSL2; AKT1; DRD2; DRD3; PDGFRA; PDGFRB; DSP; FGFR4; KDR; FLT4; FLT1; CTSV 2025-04-02 Niraparib Y Y N N 2017 N DB11793 L01XK02 CHEMBL1094636 Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer PARP2; BRCA1; BRCA2; GNAI2; IDH1; GNAI2P1; ARID1B; PARP1; ATR; MYCN; PTEN; ATM; SLFN11; CHEK2; RB1; RAD51D; RAD51C 2025-04-02 Nirogacestat Hydrobromide N Y N N 2023 N DB12005 L01XX81 CHEMBL4298153 Progressive Desmoid Tumors APP; CTNNB1; PSEN1; NOTCH2; PSENEN; APH1A; NOTCH3; APH1B; NOTCH4; NOTCH1; GLUL; NCSTN; PSEN2; APC 2025-04-02 Nivolumab Y Y N Y 2015 N DB09035 L01FF01 CHEMBL2108738 Advanced Renal Cell Cancer; Classical Hodgkin's Lymphoma; Hepatocellular Carcinoma; Low Risk Advanced Renal Cell Cancer; Melanomas; Metastatic Colorectal Cancer (MCRC); Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Metastatic Small Cell Lung Cancer; Metastatic Squamous Cell Carcinoma of the Head and Neck; Metastatic Urothelial Carcinoma (UC); Recurrent Head and Neck Squamous Cell Carcinoma; Unresectable Melanoma; Intermediate risk Advanced Renal Cell Cancer; Locally advanced Urothelial Carcinoma FGFR3; CD274; HLA-DRA; EGFR; ERBB2; BRAF; ALK; ATM; GM2A; PTEN; MDM4; IDH1; MLH1; MSH6; PMS2; PBRM1; ARID1A; KRAS; STK11; PIK3CA; TP53; TBXT; MDM2; CDK12; NRAS; PDCD1 2025-04-02 Obecabtagene Autoleucel N Y N N 2024 N DB17362 L01XL12 CHEMBL5095440 Relapsed or refractory B-cell precursor acute lymphoblastic leukemia 2025-03-31 Obinutuzumab Y Y N N 2013 N DB08935 L01FA03 CHEMBL1743048 Refractory Follicular Lymphoma; Previously untreated Chronic lymphocytic leukemia MS4A1; TP53; GATM 2025-04-02 Odronextamab Y N N N 2024 DB16684 CHEMBL4298084 Relapsed/refractory B-Cell non-Hodgkin lymphoma CD3D; CD3E; CD3G; MS4A1 2025-04-02 Ofatumumab Y Y N N 2009 N DB06650 L04AA52; L01FA02 CHEMBL1201836 Chronic Lymphocytic Leukaemia (CLL); Chronic Lymphocytic Leukemia (CLL) - Refractory; Progressive Chronic Lymphocytic Leukaemia (CLL); Recurrent Chronic Lymphocytic Leukaemia (CLL) GATM; MS4A1 2025-04-02 Olaparib Y Y N N 2014 N DB09074 L01XK01 CHEMBL521686 Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer FFAR1; PARP1; MYC; HDAC2; CHEK1; ATM; TP53; PALB2; ESR1; FLT3; PARP2; PPP2R2A; TET2; RAD51D; ARID1B; RAD51C; BRAF; MYCN; RB1; SF3B1; PIK3CA; ATR; KDM6A; FANCA; BAP1; PARP3; DNMT3A; VHL; IDH1; GNAI2P1; PTEN; RAD51B; CDK12; NRAS; GNAI2; CHEK2; BRCA1; BRCA2; BARD1; RAD54L; ATRX; ERBB2; ESR2; PGR; JAK2; IDH2 2025-04-02 Olaratumab Y Y N N 2016 N DB06043 L01FX10 CHEMBL1743049 Soft Tissue Sarcoma (STS) PDGFRA; DPP4 2024-07-24 Olutasidenib N Y N N 2022 N DB16267 CHEMBL4297610 Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML) IDH1; GPX1P2 2024-07-24 Omacetaxine Mepesuccinate N Y N N 2009 N DB04865 L01XX40 CHEMBL46286 Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia BCR; BIRC5; FLT3; TERT; ABL1 2025-04-02 Osimertinib Y Y N N 2015 N DB09330 L01EB04 CHEMBL3353410 Metastatic Non-Small Cell Lung Cancer ABCG2; EGFR; ROS1; MET; STAT3; TP53; ALK; PTEN; DXO; BRAF; PIK3CA; NRAS; ERBB2; CTNNB1 2025-04-02 Oxaliplatin N Y Y Y 2002 Y DB00526 L01XA03 CHEMBL414804 Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer BCL2; ATP7B; BRAF; MLH1; MT1A; IGF2BP2; CSMD1; ABCC2; MGAT4A; GSTP1; PARD3B; TP53; ABL1; ATM; ABCC5; GCKR; XRCC3; BAX; PTEN; MSH6; ZEB1; CXCL10; ATP7A; KRAS; DKK1; PTGS2; KLC3; PIK3CA; BRCA1; ABCC1; GNA13; FOXC2; FGFR2; DPYD; PIN1; SELE; KCNQ1; MTHFR 2025-04-02 Paclitaxel Y Y N Y 1992 Y DB01229 L01CD01 CHEMBL428647 Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer TUBA4A; TP53; MSH6; SLCO1B3; BCL2; EPHA5; ARHGEF10; CDKN2A; GSTM1; PGP; GSTT1; NRG3; RAF1; TUBB; CHEK1; MLH1; FNTB; BRCA1; ERBB2; GCF1; RRM1; NOP2; TUBB4A; PTEN; TUBA1B; TUBA3C; MISP; HRAS; CDK2; ABCG2; FOS; CYP3A; FGD4; TUBB2B; ERCC2; AR; CASP3; EPHA6; RB1; MAP3K1; ASS1; ABCC1; SLC29A1; TUBB8; TUBA3E; SLCO1B1; NFE2; NAT2; ABCC2; SYK; SOD2; TUBB1; CYP3A5; ETS2; EIF4E2; TUBB2A; TIGD1; LIG3; EIF4EBP1; EGFR; ACSS2; PIK3CG; FCGR2A; ROS1; CDKN1A; BIRC5; JAK2; SPIDR; MYB; CBR3; DSCAM; BDNF; E2F1; FZD3; TLE3; KRAS; AURKA; NRG1; TRIM5; NR1I2; TUBA1C; AFG2A; ABCC10; CXCL8; MMP2; IL2RA; STMN1; TUBB6; ATM; PIK3CA; RAD51C; ERCC1; MAD1L1; ABCB1; FASN; EMSY; TUBA1A; LIF; TUBB4B; GMNN; FGFR1; NBEAP1; ABCC3; DDIT3; PDCD4; TOP2A; GSTP1; EDNRB; TUBB3; TUBA3D 2025-04-02 Padeliporfin Y N N N 2017 N DB15575 L01XD07 CHEMBL4298112 Low-Risk Prostate Cancer of the one lobe only 2020-09-17 Palbociclib Y Y N N 2015 N DB09073 L01EF01 CHEMBL189963 Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer MAPK8; CLK2; CDK4; RB1; ERBB2; ESR1; CDK6; PIK3CA; CCNE2; CCNE1; PRKAA1; ESR2; CCND2; MET; DAPK3; TP53; PTEN; TAOK1; CCND3; MAPK9; CDK9; MST1R; EIF4EBP1; CHEK1; DYRK1A; RET; ROCK2; PGR; KRAS; BRAF; ALK; DYRK1B; NRAS; CDK5; LRRK2; CDKN2B; PRKD3; CHEK2; SMARCB1; PRKX; CCND1; RPS6KA3; FLT3; CDKN2A; SMARCA4; CLK4; MAP4K5; NEK2; PAK4; MAP4K2; MAP4K4 2025-04-02 Panitumumab Y Y N N 2006 N DB01269 L01FE02 CHEMBL1201827 Metastatic Colorectal Cancer (MCRC) PTEN; TGFA; PIK3CA; MAP2K1; HRAS; KRAS; NRG1; AREG; EREG; HBEGF; CDKN2A; NRG3; BTC; MET; DXO; EGFR; NRG2; TP53; NRAS; BRAF 2025-04-02 Panobinostat Y Y N N 2015 N DB06603 L01XH03 CHEMBL483254 Refractory Multiple Myeloma HDAC2; HDAC1; GDF2; MYCN; HDAC6; HDAC11; BAP1; HDAC8; HDAC10; SIRT4; SIRT7; GART; SIRT3; IDH1; HDAC4; SIRT5; HDAC9; SIRT1; GDF9; GAS2; KMT2A; GARS1; GAS1; GAPDHP1; SMARCB1; SIRT6; BRAF; HDAC7; SIRT2; HDAC3; HDAC5; ACTL6A 2025-04-02 Pazopanib Y Y N N 2009 Y DB06589 L01EX03 CHEMBL477772 Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer NR1I2; LCK; FGFR2; FGFR1; IGF1R; KDR; CYP2C8; FYN; PDGFRB; PDGFRA; MET; FLT4; AURKA; FLT1; ABL1; HFE; DPYSL2; HLA-B; AR; DRD1; LTK; TP53; CXCL8; NRAS; RET; HDAC2; DRD2; MAPK9; MAPK8; PPARD; TAOK1; TNK2; DPYD; SCGB3A1; VHL; YES1; HIF1A; LIMK1; VEGFA; NF1; DPP6; PBRM1; CDK7; FGFR3; DPT; CYP3A4; MTOR; AURKB; CSF1R; UGT1A1; NEK2; ALK; ITK; DRD3; PTK2; MAP4K4; KIT 2025-04-02 Pegaspargase Y Y N Y 1994 N DB00059 L01XX24 CHEMBL2108546 Acute Lymphoblastic Leukaemias (ALL) HLA-DQB1; BMP7; HLA-DQA1; GATA3; LINC00251; APOC3; DOK5; UGT1A1; HLA-DRB1; IGHMBP2; PNPLA3; CPT1A; ARHGAP28; APOA5; TPMT 2025-04-02 Peginterferon Alfa-2b Y Y N N 2001 N DB00022 L03AB10 CHEMBL1201561 Melanomas HLA-B; SLC28A2; SLC6A4; DHODH; CASP1; KIR2DS2; JAK2; SOCS3; CYP2R1; HLA-C; CXCL10; OAS1; IFNL3; TUT7; SLC29A1; IL18; MICB; EGFR; IL6; HLA-DPA1; DNAAF9; IFNAR1; IFIT1; OASL; HLA-A; VDR; IFNAR2; CTLA4; CARD16; IL21R; KLRK1; IFNA2 2025-04-02 Pembrolizumab Y Y N Y 2014 N DB09037 L01FF02 CHEMBL3137343 Advanced Renal Cell Carcinoma; Cervical Cancers; Colorectal Cancers; Metastatic Melanoma; Metastatic Solid Tumors; Unresectable Melanoma; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Locally advanced gastroesphageal juntion adenocarcinoma; Metastatic gastroesphageal juntion adenocarcinoma; Metastatic nonsquamous non-small cell lung cancer; Recurrent, metastatic Head and Neck Squamous Cell Carcinoma; Refractory, metastatic Non small cell lung cancer; Refractory, relapsed Hodgkin Lymphoma; Refractory, relapsed Mediastinal Large B-cell Lymphoma; Unresectable Solid Tumors PDCD1; JAK2; PTEN; ERBB2; JAK1; ARID1A; FGFR3; KRAS; ALK; KIT; BRAF; FBXW7; TP53; CD274; NRAS; MSH6; EGFR; POLE; ROS1; CDK12; STK11; MET; FGFR1; MLH1; PDCD1LG2; IDH1; B2M; PIK3CA; MDM2; PBRM1; MDM4; HLA-DRA; GM2A 2025-04-02 Pemetrexed Y Y N N 2004 Y DB00642 L01BA04 CHEMBL225072 Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma XRCC1; DHFR; SLC46A1; GCGR; TYMS; KRAS; SLC19A1; FOLR3; VEGFA; EXO1; ROS1; EGFR; ATIC; SLC22A8; MTHFD1; RRM1; ALK; MTHFR; GGH; HRAS; ABCC2; ERCC2; PTEN; CAMKK2; GART; CD274 2025-04-02 Pemigatinib Y Y N N 2020 N DB15102 L01EN02 CHEMBL4297522 Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas DPYSL2; FGFR1; FGFR3; DR1; FGFR2; DPYSL3 2025-04-02 Pentostatin N N Y N 1991 Y DB00552 L01XX08 CHEMBL1580 B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome PRKAA1; CCR1; ADA 2025-04-02 Pertuzumab Y Y N N 2012 N DB06366 L01FD02 CHEMBL2007641 Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer ERBB2; BRAF; ESR2; ESR1; ERBB3; EN1; EGFR; PGR 2025-04-02 Pertuzumab, Trastuzumab, Hyaluronidase Y Y N N 2020 Not found in DrugBank L01XY02 2021-10-28 Pipobroman N N Y N 1966 DB00236 L01AX02 CHEMBL1585 NFE2L2; KDM4E; ALDH1A1 2024-07-24 Pirarubicin N N N Japan N DB11616 L01DB08 CHEMBL2354444 USP1; KMT2A; HTT; GLS; ABCC1; POLK; MYCN; TP53; FEN1 2025-04-02 Pirtobrutinib Y Y N N 2023 N DB17472 L01EL05 CHEMBL4650485 Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma IGH; BTK; EFNB2; TP53 2025-04-02 Pixantrone Y N N N 2012 N DB06193 L01DB11 CHEMBL167731 Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma TOP2A 2024-02-07 Polatuzumab Vedotin Y Y N N 2019 N DB12240 L01FX14 CHEMBL3301582 Diffuse Large B-Cell Lymphoma (DLBCL) GPER1 2025-04-02 Polyestradiol Phosphate N N Y N 1957 DB09369 L02AA02 CHEMBL1201477 ESR1; AFP; NOS1 2025-04-02 Pomalidomide Y Y N N 2013 Y DB08910 L04AX06 CHEMBL43452 Refractory Multiple Myeloma CRBN; CUL4A; DDB1; RBX1 2025-04-02 Ponatinib Y Y N N 2012 N DB08901 L01EA05 CHEMBL1171837 Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia RET; BCR; FGFR2; FLT3; BRAF; PDGFRA; FGFR3; EIF4EP1; FAP; YES1; RIPK2; ABL2; PTK2B; SMARCA4; FGFR4; PDGFRB; CDK19; ABI1; FGFR1; SRC; FANCG; ABL1; KDR; EML4; KRAS; KIT 2025-04-02 Porfimer Y Y N N 1995 N DB00707 L01XD01 CHEMBL1201481 Esophageal Cancers; Completely obstructive Non-small cell lung cancer; Microinvasive endobrachial Non-small cell lung cancer; Partially obstructive Non-small cell lung cancer 2020-09-17 Pralatrexate Y Y N N 2009 Y DB06813 L01BA05 CHEMBL1201746 Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified DHFR; RFC1; PDF 2025-04-02 Pralsetinib Y Y N N 2020 N DB15822 L01EX23 CHEMBL4297597 Metastatic RET-fusion Non Small Cell Lung Cancer DRD2; RET; EML4; KIF5B; HRAS; PTK2B; CCDC6 2025-04-02 Prednisolone Y Y N Y 1955 Y DB00860 S03BA02; S02BA03; S01CB02; S01BA04; R01AD02; H02AB06; D07XA02; D07AA03; C05AA04; A07EA01 CHEMBL131 Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF) GATA3; PNPLA3; ALPP; CYBA; ANXA1; RPS19; CYP3A5; CD34; MTHFR; FCGR3A; NR3C1; FCGR3B; AR; TG; PLG; BAX; TSPYL1; BGLAP; LCAT; DSE; BDM; TAT; CYP3A4; NFE2L2; NR3C2; G6PD; HMGB1; RAC2 2025-04-02 Prednisone N Y Y N 1955 Y DB00635 H02AB07; A07EA03 CHEMBL635 Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF) NR3C1; CYBA; GSTM1; AR; ABCB1; BMP7; CYP3A4; ITGB2; BDM; TG; TYMSOS; SLC19A1; LINC00251; ATM; CYP2D6; CYP2C19; CYP1A2; IFNG; GATA3; ATF5; EDNRA; GSTP1; MIR4268; NCF4; CALCA; HSD17B10; ANXA1; MYC; CHEK2; PTPRC; CXCL12; CYP2C9; APOE; MC2R; TPMT; NOS3; DOK5; VWF; GSTA1; NFATC1; MBP; TYMS; CTLA4; MIR3117; CYP3A5 2025-04-02 Procarbazine N Y Y Y 1969 N DB01168 L01XB01 CHEMBL1321 Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease CSF2; ALOX15; CYP1A2; BAX; EPM2AIP1 2025-04-02 Quizartinib Y Y N N 2023 N DB12874 L01EX11 CHEMBL576982 Newly Diagnosed Acute Myeloid Leukemia (AML) FLT3; PDGFRA; DNMT3A; JAK3; PTK2B; DPP4; CSF1R; FGF2; PDGFRB; DPT; NRAS; IDH2; DPYS; RET; DPYD; CBL; TET2; DPP6; KIT 2025-04-02 Racotumomab N N N Cuba, Argentina N DB13045 CHEMBL1743059 2020-09-17 Radium 223 Dichloride Y Y N N 2013 N DB08913 V10XX03 CHEMBL2107816 Castration resistant, metastatic Prostate cancer 2020-09-17 Raltitrexed N N Y Canada N 1996 N DB00293 L01BA03 CHEMBL225071 Advanced Colorectal Cancer; Pleural Mesotheliomas DHFR; BCL2 2025-04-02 Ramucirumab Y Y N N 2014 N DB05578 L01FG02 CHEMBL1743062 Advanced Gastric Cancer; Advanced gastro-esophageal junction adenocarcinoma; Refractory, metastatic Colorectal cancer; Refractory, metastatic Non small cell lung cancer EGFR; KDR; KRAS; PDGFRA; DRD2; ALK 2025-04-02 Ranimustine N N N Japan N DB13832 L01AD07 CHEMBL2105348 2020-09-22 Realgar-Indigo Naturalis Formulation N N N China Y 2009 Not found in DrugBank L01XX27 Acute promyelocytic leukaemia 2021-03-10 Regorafenib Y Y N N 2012 N DB08896 L01EX05 CHEMBL1946170 Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor FLT4; PDGFRB; EGFR; PDGFRA; RAF1; KDR; FBXW7; FRK; KRAS; BRAF; DDR2; ABL1; FLT1; NRAS; RET; ARAF; EPHA2; DRD2; FGFR3; ZHX2; EFNA2; FGFR2; MAPK11; YES1; PTEN; TEK; MAP2K1; NTRK1; VHL; FGFR1; KIT; VEGFA; PIK3CA 2025-04-02 Relatlimab , Nivolumab Y Y N N 2022 DB14851 L01XY03 CHEMBL3990044; CHEMBL2108738 Metastatic Melanoma, Unresectable Melanoma 2024-07-25 Relugolix Y Y N N 2020 N DB11853 L02BX04 CHEMBL1800159 Advanced Prostate Cancer LHCGR; GNRHR 2025-04-02 Repotrectinib Y Y N N 2023 N DB16826 L01EX28 CHEMBL4298138 locally active or metastatic non-small cell lung cancer EML4; EPHB2; NTRK2; DRD5P1; NTRK3; NTRK1; CD74; SDC4; ALK; ROS1; DRD5P2; DTX1; HBEGF; DRG2 2025-04-02 Retifanlimab Y Y N N 2023 N DB15766 L01FF10 CHEMBL4298037 Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma GM2A 2024-07-24 Revumenib N Y N N 2024 N DB18515 CHEMBL4650827 Relapsed/refractory leukemia with KMT2A translocation 2025-03-31 Ribociclib Y Y N N 2017 N DB11730 L01EF02 CHEMBL3545110 Advanced Breast Cancer; Metastatic Breast Cancer CDKN2A; CDK4; PGR; ERBB2; RB1; ESR1; JAK2; PIK3CA; NRAS; CCND3; PTEN; SMARCA4; ESR2; ALK; CCND2; CCND1; BRAF; CDK6 2025-04-02 Ripretinib Y Y N N 2020 N DB14840 L01EX19 CHEMBL4216467 Advanced Gastrointestinal Stromal Tumor (GIST) PDGFRA; KIT; DPT; PDGFRB; CYP3A4 2025-04-02 Rituximab Y Y N Y 1997 N DB00073 L01FA01 CHEMBL1201576 Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (NHL) MS4A1; TGFB1; XIAP; TET2; CXCL12; TP53; CXCL13; JAK2; RPS19; GATM; GSTA1; FCGR2A; IL6; NCF4; ABCB1; CYBA; FCGR3A; IL2 2025-04-02 Rituximab, Hyaluronidase N Y N N 1997 N DB00073 L01XC02 CHEMBL1201576 Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (NHL) MS4A1; TGFB1; XIAP; TET2; CXCL12; TP53; CXCL13; JAK2; RPS19; GATM; GSTA1; FCGR2A; IL6; NCF4; ABCB1; CYBA; FCGR3A; IL2 2025-04-02 Romidepsin Y Y N N 2009 Y DB06176 L01XH02 CHEMBL343448 Refractory peripheral cutaneous T-cell lymphoma HDAC1; GAS2; HDAC9; HDAC5; CTAG1B; HDAC10; HDAC2; HDAC4; ERBB2; GDF2; HDAC3; HDAC11; HDAC7; KMT2A; GARS1; GAS1; CDKN1A; ABCB1; GART; BRAF; GDF9; GAPDHP1; CDKN2D; ADAMTSL4-AS1; HDAC8; HDAC6; MSTN; BIRC5 2025-04-02 Rucaparib Y Y N N 2016 N DB12332 L01XK03 CHEMBL1173055 Advanced Ovarian Cancer PARP3; PARP2; CHEK2; DYRK1A; PTEN; CYP2D6; CDK1; RAD51C; BRCA1; RAD51B; PALB2; IDH1; PIM1; PRKD2; NRAS; BRAF; RAD51D; BRCA2; ATM; PARP1; CYP1A2; YES1; GNAI2; ATR 2025-04-02 Ruxolitinib Y Y N N 2011 N DB08877 L01EJ01 CHEMBL1789941 Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera CYP3A4; JAK1; JAK2; VHL; SH2B3; TYK2; EPHB2; JAK3; CSF3R; BRAF; TP53; IL7R; FLT3; PLAUR; EPHB1; EPHB3 2025-04-02 Sacituzumab Govitecan Y Y N N 2020 N DB12893 L01FX17 CHEMBL3545262 Metastatic Triple-negative Breast Cancer UGT1A1; ESR2; TACSTD2; ESR1; TOP1; ERBB2; UTS2R; BRCA2; BRCA1 2025-04-02 Selinexor Y Y N N 2019 N DB11942 L01XX66 CHEMBL3545185 Refractory Multiple Myeloma FLT3; XPO1; TET2; TP53; H2AX 2025-04-02 Selpercatinib Y Y N N 2020 N DB15685 L01EX22 CHEMBL4559134 Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer RET; CCDC6; KIF5B; PTK2B 2025-04-02 Serplulimab Y N N N 2025 N DB17451 L01FF12 CHEMBL4594550 PDCD1 2025-04-02 Sipuleucel-T N Y N N 2010 N DB06688 L03AX17 CHEMBL1237024 Asymptomatic, metastatic hormone-refractory Prostate cancer; Minimally symptomatic, metastatic hormone-refractory Prostate cancer ACP3 2024-02-07 Sonidegib Y Y N N 2015 N DB09143 L01XJ02 CHEMBL2105737 Refractory, locally advanced Basal cell carcinoma ALOX12; SMO; FLT3; PTCH1; MYCN; SUFU 2025-04-02 Sorafenib Y Y N N 2005 Y DB00398 L01EX02 CHEMBL1336 Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma MAPK6; BRAF; DPT; RAF1; PTPN6; FLT4; DYRK3; FLT3; PDGFRA; MAPK9; KIT; PDGFRB; FAH; VEGFB; FGFR1; KRAS; RPS6KB1; NTSR1; NF1; ARAF; YES1; PTEN; CDK8; MAPK12; NTRK2; MAPK13; PTK2B; NTRK1; FGF3; ABCC2; SLC15A2; CBL; MAPK3; FGF2; TSC1; HIF1A; NFE2L2; ATXN2; DUSP2; TNF; CAMK2B; ABCG2; MKNK2; JAK3; ARID1A; SLC22A1; SLCO1B1; MAP4K5; CYP2B6; CSF1R; MINK1; AURKB; WWOX; MC4R; ADAMTS18; CYP3A4; SLK; MAPK1; EIF4EP1; DRD2; MAP2K1; PAX8; DPP6; EFNA2; VEGFA; GMNN; CYP2C8; LYN; VHL; DPYSL2; PIK3CA; BLK; EPHA2; PLK4; TAOK1; ABCB1; HIPK4; HMOX1; LIMK1; UGT1A9; CYP2C9; PRKCE; MAPK10; MAPK8; CDK19; FLT1; IRAK1; AR; ABL1; TSC2; AURKA; DPYS; NOS3; IDH2; MAP2K6; MAPK11; AXL; KDR; RET; MAPK4; NR1I2; HIPK2; FGFR3; CDH13; EGFR; TP53; CTNNB1; MAP3K20; ZHX2; VEGFC; NRAS; MAPK14; NTRK3; MAPK7; SRPK1 2025-04-02 Sotorasib Y Y N N 2021 N DB15569 L01XX73 CHEMBL4535757 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer GPM6B 2025-04-02 Streptozocin N Y N N 2005 N DB00428 L01AD04 CHEMBL1651906 Stage 4 islet cell carcinoma CSF2; TRPV1; HRAS; ATF2; DDIT3; CYP2D6; CTSD; PTGER4; ACP5; HP; KCNA2; ENO2; CYP7B1; PRKAA1; GALP; UCP1; SLC16A3; SLC2A5; SLC2A4; MT1H; SSTR1; PIK3CA; SST; OGA; CD40; RAMP3; ADCYAP1; THRSP; SLC5A1; TH; LCAT; SI; NTRK1; HGF; IGFBP1; VWF; MYO9B; SFTPB; KCNJ11; CDKN1B; PREP; MMP2; BCL2; SULT1A2; TGFB1; S100B 2025-04-02 Sugemalimab Y N N N 2024 DB16641 L01FF11 CHEMBL4594535 Metastatic non-small cell lung cancer (NSCLC) CD274 2024-11-28 Sunitinib Y Y N N 2006 Y DB01268 L01EX01 CHEMBL535 Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors DRD3; RET; KDR; PDGFD; PDGFRA; FLT3; KIT; PDGFB; MKI67; CA9; CTSV; FGFR2; VHL; TP53; FLT1; DPP6; NR1I2; SLC22A5; PDGFRB; PBRM1; FLT4; IL4R; VEGFC; PTK2B; PTPN12; PDGFC; VEGFA; DPT; NR1I3; CYP3A4; NOS3; DRD2; SLCO1B3; CXCL8; HIF1A; DPYS; LATS2; FGFR1; HMOX1; CSF1R; PTPRB; PDGFA; DPYSL2; POR; KDM5C; YES1; BAP1; PTEN 2025-04-02 Tafasitamab Y Y N N 2020 N DB15044 L01FX12 CHEMBL4298047 Refractory Diffuse large B-cell lymphoma NOS; Relapsed Diffuse large B-cell lymphoma NOS TNFRSF8; CD19; GMFB 2025-04-02 Tagraxofusp Y Y N N 2018 N DB14731 L01XX67 CHEMBL4297573 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) IL3RA; EEF2; CSF2RB 2025-04-02 Talazoparib Y Y N N 2018 N DB11760 L01XK04 CHEMBL3137320 Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer MLH1; BRCA1; GNAI2; ATR; ERBB2; ATRX; IDH1; BRAF; MYCN; TET2; RAD51D; FLT3; PALB2; RB1; BRCA2; GNAI2P1; PARP2; SLFN11; DNMT3A; ATM; IDH2; CHEK2; NRAS; RAD51C; PARP1; PTEN; PSMD4; EGFR 2025-04-02 Talimogene Laherparepvec Y Y N N 2015 N DB13896 L01XX51 CHEMBL2108727 Unresectable Skin Lesion CSF2RA; CSF2 2025-04-02 Talquetamab Y Y N N 2023 N DB16678 L01FX29 CHEMBL4594503 Relapsed and Refractory Multiple Myeloma CD3G; CD3E; CD3D; GPRC5D 2025-04-02 Tamoxifen N Y Y Y 1977 Y DB00675 L02BA01 CHEMBL83 Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer BGLAP; F2; FMO3; TP53; GAPDH; ALDH3B1; PLD1; PLD2; ESR1; CYP2B6; BRCA1; MYOD1; NRG1; NTRK1; SLCO2B1; GGT1; VDR; CBX1; EDN1; AURKA; IGF1R; KDM4A; E2F7; CETP; PIP; CYP3A4; ZNF423; NR1I2; COL18A1; EHMT2; IDH1; F5; FMO1; CCNA2; MUC16; NF1; HEXB; TGFB1; PIK3CA; SLCO1A2; RRAS2; CYP1A2; ERBB2; NCOA3; BCYRN1P2; BAZ2B; HSPB2; CYP2C9; GMNN; TFF3; UGT1A4; CYP2D6; KLK3; PGR; DHFR; NCOA1; ZNF613; TGM2; LRMDA; CYP19A1; CCND1; ATXN2; ESR2; NFE2L2; TYMS 2025-04-02 Tarlatamab N Y N N 2024 N DB17256 L01FX33 CHEMBL5095292 Extensive-stage small cell lung cancer GLRA2 2024-07-24 Tazemetostat N Y N N 2020 N DB12887 L01XX72 CHEMBL3414621 Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma FLT3; BRAF; SMARCA4; EZH2; IDH1; SMARCB1; KDM6A; RB1 2025-04-02 Tebentafusp Y Y N N 2022 N DB15283 L01XX75 CHEMBL4297990 Metastatic Uveal Melanoma (UM), Unresectable Uveal Melanoma PMEL; CD3G; TRBV20OR9-2; HLA-A 2025-04-02 Teclistamab Y Y N N 2022 N DB16655 L01FX24 CHEMBL4594505 Multiple Myeloma CD3D; TNFRSF17; CD3E; CD3G 2025-04-02 Tegafur, Gimeracil, Oteracil Y N N N 2011 DB09256 L01BC03; L01BC53 CHEMBL20883 Advanced Gastric Cancer CDX2; TYMS; FASTKD3; DPYD; UMPS; EGFR; MTRR; SMAD7 2025-04-02 Tegafur, Uracil N N N Japan N DB09256 L01BC03; L01BC53 CHEMBL20883 Advanced Gastric Cancer CDX2; TYMS; FASTKD3; DPYD; UMPS; EGFR; MTRR; SMAD7 2025-04-02 Temoporfin Y N N N 2001 N DB11630 L01XD05 CHEMBL500576 Advanced Head and Neck Squamous Cell Carcinoma 2020-09-17 Temozolomide Y Y N N 1999 Y DB00853 L01AX03 CHEMBL810 Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome ATR; ALK; MSH6; ATRX; GSTP1; HDAC4; PTEN; CDKN2A; H2AX; MYC; TP53; CSF2; RAD51B; TSC2; PIK3CA; PRL; IDH1; SLFN11; BRCA2; MGMT; ATM 2025-04-02 Temsirolimus Y Y N N 2007 Y DB06287 L01EG01 CHEMBL1201182 Advanced Renal Cell Carcinoma MTOR; PIK3CA; BRAF; KRAS; FKBP1A; NF2; CTNNB1; TSC2; FBXW7; RPTOR; PTPRD; ETFB; VHL; PTEN; TSC1 2025-04-02 Tepotinib Y Y N N 2021 N DB15133 L01EX21 CHEMBL3402762 Metastatic Non-Small Cell Lung Cancer MET; DRD4; ALK; EGFR 2025-04-02 Thalidomide Y Y N Y 1998 N DB01041 L04AX02 CHEMBL468 Multiple Myeloma (MM); Waldenstrom's Macroglobulinemia (WM); Treatment naive multiple myeloma HLA-B; CRBN; NFKB1; TNF; FGFR2; SPG7; NAT2; SULT1C4; MECOM; F2R; PTGS2; ERCC1; PPARD; FGF2; SLC10A2; CYP2C19; IL6R; RPL13; GSTT1; FCGR3A; ATP7A; CUL4A; XRCC5; CYP4B1; CHST3; CYP1A2; SNORD68; ITGB2; RBX1; HGF; CTLA4; VWF; FCGR3B; ABCC6; CTNNB1; DDB1; VEGFA 2025-04-02 Thioguanine N Y N N 1966 N DB00352 L01BB03 CHEMBL727 Acute Nonlymphocytic Leukemia; Nonlymphocytic Acute myeloid leukemia SLC28A3; IGHMBP2; GDA; CPT1A; NAT1; MGMT; UGT1A1; AR; NT5C2; NFE2L2; PNPLA3; HPGD; IMPDH2; IMPDH1; BMP7; ABCC4; EHMT2; GATA3; ACHE; KDM4A; GATA2; XDH; TPM3; HBB; TPMT; NUDT15; GGH; IDH1; LINC00251; MYC; PRPS1; PAX8; DOK5 2025-04-02 Thiotepa Y Y N N 1959 Y DB04572 L01AC01 CHEMBL671 Adenocarcinoma of the Ovaries; Breast Adenocarcinoma; Papillary transitional cell carcinoma of bladder; Malignant effusion EHMT2; ALDH3A1; TP53; ALDH1A1; GSTP1; HPGD; CYP2B6; VDR; GMNN; AR 2025-04-02 Tisagenlecleucel Y Y N N 2017 N DB13881 L01XX71 CHEMBL3301574 Refractory B-cell precursor acute lymphoblastic leukemia; Second or later relapsed B-cell precursor acute lymphoblastic leukemia CD19; MS4A1 2025-04-02 Tislelizumab Y N N China N 2023 N DB14922 L01FF09 CHEMBL4297840 Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma PDCD1 2025-04-02 Tisotumab Vedotin Y Y N N 2021 N DB16732 L01FX23 CHEMBL4297841 Recurrent or metastatic cervical cancer TUBB4B; F3; TUBA3C; TUBA1C; TUBB2A; TUBB1; TUBB8; TUBB4A; TUBA3E; TUBB2B; TUBA1B; TUBB; TUBA4A; TUBB6; TUBA1A; TUBB3 2025-04-02 Tivozanib Y Y N N 2017 N DB11800 L01EK03 CHEMBL1289494 Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma KDR; FLT1; FLT4; YES1; DRD3; NRAS; DRD1; BRAF; DRD2 2025-04-02 Topotecan Y Y N N 1996 Y DB01030 L01CE01 CHEMBL84 Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer RB1; ABCG2; ABCB1; HBB; MUC16; TOP1; PAX8; ALK; TYMS; TSG101; AKT1; HIF1A; AR; PLK1; KMT2A; PTEN; NFE2L2; USP1; PIK3CA; DDO; IDH1; TP53; BDNF; TOP1MT 2025-04-02 Toremifene Y Y N N 1997 Y DB00539 L02BA02 CHEMBL1655 Desmoid Tumors; Metastatic Breast Cancer AR; ESR1; ESR2; CYP3A4; CYP1B1; KDM4A; GMNN; HNF4A; CD80; PLIN1; TGFB1; CYP2D6; PGR 2025-04-02 Toripalimab Y Y N N 2023 N DB15043 L01FF13 CHEMBL4297843 Metastatic and Recurrent Nasopharyngeal Carcinoma GM2A 2024-10-30 Tovorafenib N Y N N 2024 N DB15266 CHEMBL3348923 Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation RAF1; BRAF; EFNA2; NRAS; ZHX2; ARAF 2025-04-02 Trabectedin Y Y N N 2015 N DB05109 L01CX01 CHEMBL450449 Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma PARP1; FGFR2; TP53; ABCC2; ABCB1 2025-04-02 Trametinib Y Y N N 2013 N DB08911 L01EE01 CHEMBL2103875 Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation FLT3; ABL1; CSF3R; DDX43; BRAF; EML4; RASA1; PIK3CA; MAP2K1; ERBB3; APC; MAP2K2; ATXN1L; NF1; DUSP6; VHL; TP53; ETV4; RAF1; ETV1; FGFR2; KRAS; CTNNB1; ARAF; RB1; ATM; NRAS; PTEN; FGFR1; CIC; MAP2K6; RET; ALK; MAP2K3; ETV5; HRAS; NR2F6; PRKCH; G6PD; MAP2K7; KIT; CDKN2A; MAP2K5; MET; MAP2K4; DNMT3A; IDH1 2025-04-02 Trastuzumab Y Y N Y 1998 N DB00072 L01FD01 CHEMBL1201585 Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma ERBB2; FCGR3A; KRAS; EPCAM; PTEN; IFNG; AKT2; BIRC5; ARID1A; ESR1; PGR; PPCDC; CBR3; RAD51C; PIK3CA; ABCB1; EGFR; FCGR2A; ERBB3; HSPB2; RNF8; ANXA1; HGF; PIK3CG; ESR2; EN1; MET 2025-04-02 Trastuzumab Deruxtecan Y Y N N 2019 N DB14962 L01FD04 CHEMBL4297844 HER2 Positive Breast Cancers ESR2; ERBB2; ESR1; TOP1 2025-04-02 Trastuzumab Emtansine Y Y N N 2013 N DB05773 L01FD03 CHEMBL1743082 Refractory, metastatic Non small cell lung cancer ERBB2; TUBB3; TUBB4A; TUBA3E; TUBB2B; TUBB8; TUBA1B; TUBB1; TUBB4B; TUBB; TUBA1C; TUBA3C; PIK3CA; TUBB6; TUBA1A; TUBA4A; TUBB2A 2025-04-02 Trastuzumab, Hyaluronidase Y Y N N 1998 N DB00072 L01XC03 CHEMBL1201585 Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma ERBB2; FCGR3A; KRAS; EPCAM; PTEN; IFNG; AKT2; BIRC5; ARID1A; ESR1; PGR; PPCDC; CBR3; RAD51C; PIK3CA; ABCB1; EGFR; FCGR2A; ERBB3; HSPB2; RNF8; ANXA1; HGF; PIK3CG; ESR2; EN1; MET 2025-04-02 Tremelimumab Y Y N N 2022 N DB11771 L01FX20 CHEMBL2108658 Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC) CTLA4; CD274; MLH1; GLRB; MSH6; ALK; EGFR 2025-04-02 Tretinoin N Y Y N 1971 Y DB00755 D10AD01; L01XF01 CHEMBL38 FAB classification M3 Acute promyelocytic leukemia THBS1; IFNG; APOE; SLC2A1; HAS3; ERVK2; TGFBR3; RARA; BIRC5; NFE2L2; RARG; PRL; TGFB1; NRIP1; WT1; RARB; ITGB2; RARRES1; NR2E1; BCL2L2; NR2C1; APOA1; CXCL8; KAT2A; RB1; HOXD1; TPO; NPM1; FLT3; CDKN1B; P2RY2; MAPK8; MYCN; NR2C2; RPE65; RXRB; CALR; BCL2; CYP3A5; EHMT2; AMH; USP1; RXRA; PTPRZ1; TSPYL2; RXRG; HES1; SMARCA4; BCHEL1; OCLN; CD55; HIF1A; BHLHE40; IL10; TP73; ALDH1A2; VDR; BCKDHB; LIF; FAS; RET; GLI1; ALPL; CYP2C9; MDK; PTCH1; BCHE; SHH; HOXB1; XIAP; RAB40B; SPP1; TBP; NR4A1; BAX; PML; CEACAM1; SFTPA1; NOS1; DUSP6; FUS; EGR2; SMAD2; MST1; MYOD1; BCHEL3; HSPA8; KLK3; IL1R1; ADH1C; TG 2025-04-02 Trifluridine, Tipiracil Y Y N N 1980 Y DB00432 L01BC59; S01AD02 CHEMBL1129 Metastatic Colorectal Cancer (MCRC) TP53; SLC29A1; ERBB2 2025-04-02 Triptorelin N Y Y N 2000 N DB06825 L02AE04 CHEMBL1201334 Advanced Prostate Cancer GNRHR; STS 2024-07-24 Trofosfamide N N Y N DB12902 L01AA07 CHEMBL462019 Non-Hodgkin's lymphoma CYP2B6 2024-02-07 Tucatinib Y Y N N 2020 N DB11652 L01EH03 CHEMBL3989868 Breast Cancer; Unresectable Breast Cancer EN1; ERBB2; HRAS; KRAS; ERBB4; EGFR; DXO; NRAS 2025-04-02 Umbralisib N Y N N 2021 N DB14989 L01EX25 CHEMBL3948730 B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL) F7; PIK3CG; PIK3CD; ELF2 2025-04-02 Valrubicin N Y N N 1998 Y DB00385 L01DB09 CHEMBL1096885 In situ BCG-refractory Bladder carcinoma AR; TOP2A 2025-04-02 Vandetanib Y Y N N 2011 N DB05294 L01EX04 CHEMBL24828 Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer IDH1; EPHA2; ALK; CYP3A4; FLT4; RET; EPHA10; KDR; EPHA3; ROCK2; LTK; ATM; TEK; DXO; EPHA8; EPHB6; ERBB3; PTK2B; ACVR1; ABL1; KRAS; YES1; SRC; EPHB3; EPHB4; PDGFRB; MAP4K4; MTOR; MAP2K2; PTEN; BTK; EPHA7; EPHB2; EGFR; APC; EPHA1; AXL; DRD2; MAP2K1; FGFR1; TYRO3; EPHA6; MAP4K5; EPHB1; LRRK2; AURKB; ERBB2; PTK6; MAPK14; HTT; ERBB4; FYN; EPHA5; PDGFRA; GMNN; FLT1; LCK; EPHA4 2025-04-02 Vemurafenib Y Y N N 2011 N DB08881 L01EC01 CHEMBL1229517 Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer TP53; NRAS; TF; MAP2K2; BRAF; PTEN; MAP2K1; NF1; SOX10; HRAS; AKT1; FGFR2; CYP1A2; YES1; CDKN2A; STAG2; RB1; PIK3CA; STAG3; KRAS; PREX2; FAH; AKT3; MET; CIC; RAC1; MITF; TET2; EFNA2; SMARCA4; ABCB1; CYP3A; CHEK2; PIK3R2; CYP3A4; ATXN1L; CBL 2025-04-02 Venetoclax Y Y N N 2016 N DB11581 L01XX52 CHEMBL3137309 Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma ALK; TP53; KDM6A; PTEN; BCL2; MCHR1; LPAR4; ATM; FLT3; ABL1; SMARCA4; KIT; GPR22; NRAS; PIK3CA; NPM1; GPR21; IDH1; IGH; IDH2; KMT2A; BRAF 2025-04-02 Vimseltinib N Y N N 2025 N DB17520 L01EX29 CHEMBL5095202 Tenosynovial giant cell tumor CSF1R; DPT; DPYD; DPP4 2025-04-02 Vinblastine N Y Y Y 1965 Y DB00570 L01CA01 CHEMBL159 Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer TUBA3E; TUBB; BRAF; GMNN; TUBB2A; TUBB2B; TUBA1C; CSF2; CGA; CYP3A4; PTHLH; ABCB1; TRH; TUBA3D; TUBB3; GSTM1; TUBA3C; TUBB4A; TUBB1; NOP2; TUBA1A; TUBB8; MMP2; GCF1; TUBB4B; CDKN1A; TUBA4A; TUBB6; NF1; NR1I2; TBXA2R; KLK3; ABCB4; TUBA1B 2025-04-02 Vincristine N Y Y Y 1965 Y DB00541 L01CA02 CHEMBL90555 Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma TUBB; IGHMBP2; SLC5A7; ABCB4; ABL1; SMAD3; GSTA1; CYBA; ABCC3; VWF; LINC00251; TYMS; NOS3; MTHFR; TUBA4A; MIR4481; FGF2; ODC1; PIK3CA; BCR; XDH; NTF3; TUBA1C; TUBB3; ABCC10; MRPL47; CXCL12; TUBA1B; MIR4268; PIK3CG; GMNN; GATA3; TUBA3C; TUBB1; NRG1; MTR; NCF4; SYNE2; TUBB8; TUBB4A; ABCC1; TUBB2A; TOP2A; MIR3117; TUBA3E; TUBA3D; CAPG; FCGR3A; HSPB2; SRI; TUBA1A; DOK5; TUBB6; UGT1A1; TUBB4B; BAHD1; GCF1; SULF2; AR; BDNF; RALBP1; ABCB1; RAC2; CDKN1B; MIR6076; BCL2; CPT1A; CP; ACTG1; TP73; MYCN; NR1I2; BMP7; PNPLA3; TUBB2B; COCH; STIM1; AFP; TPMT; NKAIN3; ATF5 2025-04-02 Vincristine Liposome N Y N N 2012 Y DB00541 L01CA02 CHEMBL501867 Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma TUBB2A; TUBB; TUBB4B; ALK; TUBB1; HIF1A; TUBB8; TUBA1C; TUBA3E; GMNN; TUBB6; TUBB4A; TUBA3C; TUBB2B; TUBA1B; TUBA4A; NR0B1; TUBA1A; TUBB3 2025-04-02 Vindesine N N Y N 1979 N DB00309 L01CA03 CHEMBL238071 Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant ABCB1; TUBB1; TUBB; CYP3A4 2025-04-02 Vinflunine Y N N N 2009 N DB11641 L01CA05 CHEMBL2110725 Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract TUBA4A; TUBA3E; TUBB6; TUBB2B; TUBA1A; TUBB4A; TUBB2A; TUBB; TUBB3; TUBA3C; TUBB4B; TUBA1C; TUBB1; TUBA1B; TUBB8 2025-04-02 Vinorelbine N Y Y Y 1994 Y DB00361 L01CA04 CHEMBL553025 Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer TUBB; APC; TUBA3E; SMARCA4; TUBA1A; STMN1; TUBA1C; XRCC1; TUBB1; TUBB8; TUBB4A; BRCA1; TUBA3C; MTHFR; CSF2; TUBB3; TUBA1B; TUBA3D; TUBB6; TUBB4B; TUB; TUBA4A; RRM1; TUBB2A; TUBB2B; BAX 2025-04-02 Vismodegib Y Y N N 2012 N DB08828 L01XJ01 CHEMBL473417 Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma SHH; ALOX12; SMO; PTCH1 2025-04-02 Vorasidenib N Y N N 2024 DB17097 L01XM04 CHEMBL4279047 Grade 2 astrocytoma or oligodendroglioma IDH1; GRB2; IDH2; GPX1P2 2025-04-02 Vorinostat N Y N N 2006 N DB02546 L01XH01 CHEMBL98 Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma TUBB; HDAC8; TUBB4B; HDAC2; HDAC3; HDAC9; TUBB1; PTEN; IDH1; BRAF; NR0B1; GMNN; FBXW7; HDAC1; TUBA1C; TUBB3; HDAC6; BIRC5; TUBA1A; TUBB2B; MYC; TUBA1B; TUBA4A; TP53; ACE; GAPDHP1; GDF2; GNA11; GARS1; UGT2B17; TUBB2A; ERBB2; GAS1; NFE2L2; GART; TUBB6; PAX8; CHD4; TUBB4A; CFTR; TUBA3D; MSTN; HDAC4; SMARCB1; HDAC5; BAP1; TUBA3E; HDAC11; LRRC32; GAS2; TUBB8; TUBA3C; HDAC10; HDAC7; GAPDHL17; RB1 2025-04-02 Zanidatamab N Y N N 2024 N DB15471 L01FD07 CHEMBL4650256 Previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC) ERBB2 2025-04-02 Zanubrutinib Y Y N N 2019 N DB15035 L01EL03 CHEMBL3936761 Mantle Cell Lymphoma (MCL) MYD88; TP53; BTK; EFNB2 2025-04-02 Zenocutuzumab N Y N N 2024 N DB15559 CHEMBL4298025 Advanced unresectable or metastatic non-small cell lung cancer ERBB2; ERBB3 2025-04-02 Zolbetuximab Y Y N N 2024 DB15118 L01FX31 CHEMBL2109427 Locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma CLDN18 2025-04-02